UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
 
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2010

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ___________

Commission File Number 1-12031


UNIVERSAL DISPLAY CORPORATION
(Exact name of registrant as specified in its charter)

Pennsylvania
 
23-2372688
(State or other jurisdiction of
 
(I.R.S. Employer Identification No.)
incorporation or organization)
   
     
375 Phillips Boulevard
   
Ewing, New Jersey
 
08618
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (609) 671-0980

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  X    No     

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes         No     

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ___
Accelerated filer     X
Non-accelerated filer  ___ (Do not check if a smaller reporting company)
Smaller reporting company ___
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes        No  X 
 
As of May 5, 2010, the registrant had outstanding 37,646,323 shares of common stock.
 

 
 

 

TABLE OF CONTENTS
   
 
 
 


 
2


PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

   
March 31,
   
December 31,
 
   
2010
   
2009
 
ASSETS
 
CURRENT ASSETS:
           
Cash and cash equivalents
  $ 7,553,643     $ 22,701,126  
Short-term investments
    55,467,352       41,172,955  
Accounts receivable
    2,399,297       3,344,255  
Other current assets
    372,585       411,240  
                 
Total current assets
    65,792,877       67,629,576  
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
    10,624,506       11,048,763  
$16,212,271 and $15,788,490
               
ACQUIRED TECHNOLOGY, net of accumulated amortization of
    810,504       1,234,272  
$16,140,214 and $15,716,446
               
OTHER ASSETS
    245,557       227,276  
                 
TOTAL ASSETS
  $ 77,473,444     $ 80,139,887  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY
 
CURRENT LIABILITIES:
               
Accounts payable
  $ 1,620,909     $ 1,275,695  
Accrued expenses
    3,470,776       5,238,870  
Deferred license fees
    6,178,886       6,047,467  
Deferred revenue
    1,041,731       1,403,927  
                 
Total current liabilities
    12,312,302       13,965,959  
DEFERRED LICENSE FEES
    3,271,388       2,826,237  
STOCK WARRANT LIABILITY
    3,006,922       3,720,165  
                 
Total liabilities
    18,590,612       20,512,361  
                 
COMMITMENTS AND CONTINGENCIES (Note 9)
               
                 
SHAREHOLDERS’ EQUITY:
               
Preferred Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000 shares of Series A Nonconvertible Preferred Stock issued and outstanding (liquidation value of $7.50 per share or $1,500,000)
    2,000       2,000  
Common Stock, par value $0.01 per share, 50,000,000 shares authorized, 37,593,459 and 36,818,440 shares issued and outstanding at March 31, 2010 and December 31, 2009, respectively
    375,935       368,184  
Additional paid-in capital
    258,599,927       256,340,530  
Unrealized (loss) gain on available-for-sale securities
    (7,994 )     25,517  
Accumulated deficit
    (200,087,036 )     (197,108,705 )
                 
Total shareholders’ equity
    58,882,832       59,627,526  
                 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  $ 77,473,444     $ 80,139,887  
                 



The accompanying notes are an integral part of these consolidated statements.



CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

   
Three Months Ended March 31,
 
   
2010
   
2009
 
REVENUE:
           
Commercial revenue
  $ 1,830,147     $ 1,369,137  
Developmental revenue
    2,416,503       1,464,721  
                 
Total revenue
    4,246,650       2,833,858  
                 
OPERATING EXPENSES:
               
Cost of chemicals sold
    460,786       170,987  
Research and development
    4,466,631       5,219,062  
Selling, general and administrative
    2,642,246       2,622,945  
Patent costs
    781,259       731,531  
Royalty and license expense
    120,060       82,931  
                 
Total operating expenses
    8,470,982       8,827,456  
                 
Operating loss
    (4,224,332 )     (5,993,598 )
INTEREST INCOME
    75,655       253,400  
INTEREST EXPENSE
    (7,059 )     (2,643 )
GAIN ON STOCK WARRANT LIABILITY
    713,243       173,242  
                 
LOSS BEFORE INCOME TAX BENEFIT
    (3,442,493 )     (5,569,599 )
                 
INCOME TAX BENEFIT
    464,162        
                 
NET LOSS
  $ (2,978,331 )   $ (5,569,599 )
                 
BASIC AND DILUTED NET LOSS PER COMMON SHARE
  $ (0.08 )   $ (0.15 )
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE
    37,029,462       36,299,967  
                 



The accompanying notes are an integral part of these consolidated statements.



CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

   
Three Months Ended March 31,
 
   
2010
   
2009
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
  $ (2,978,331 )   $ (5,569,599 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Amortization of deferred license fees and deferred revenue
    (710,626 )     (663,634 )
Depreciation
    513,557       517,472  
Amortization of intangibles
    423,768       423,768  
Amortization of premium and discount on investments, net
    (43,619 )     (144,887 )
Stock-based employee compensation
    463,133       551,489  
Stock-based non-employee compensation
    40,848       1,998  
Non-cash expense under a materials agreement
    243,459       309,375  
Stock-based compensation to Board of Directors and Scientific Advisory Board
    149,703       71,524  
Gain on stock warrant liability
    (713,243 )     (173,242 )
(Increase) decrease in assets:
               
Accounts receivable
    944,958       637,086  
Other current assets
    38,655       (20,988 )
Other assets
    (18,281 )     (13,719 )
Increase (decrease) in liabilities:
               
Accounts payable and accrued expenses
    278,171       (498,481 )
Deferred license fees
    800,000        
Deferred revenue
    125,000       66,667  
                 
Net cash used in operating activities
    (442,848 )     (4,505,171 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchase of property and equipment
    (89,300 )     (95,801 )
Purchase of short-term investments
    (35,224,272 )     (36,479,245 )
Proceeds from sale of short-term investments
    20,939,983       19,655,000  
                 
Net cash used in investing activities
    (14,373,589 )     (16,920,046 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from the issuance of common stock
    62,659        
Proceeds from the exercise of common stock options and warrants
    722,682        
Payment of withholding taxes related to stock-based employee compensation
    (1,116,387 )     (831,877 )
                 
Net cash used in financing activities
    (331,046 )     (831,877 )
                 
DECREASE IN CASH AND CASH EQUIVALENTS
    (15,147,483 )     (22,257,094 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
    22,701,126       28,321,581  
                 
CASH AND CASH EQUIVALENTS, END OF PERIOD
  $ 7,553,643     $ 6,064,487  
                 
The following non-cash activities occurred:
               
                 
Unrealized (loss) gain on available-for-sale securities
    (33,511 )     14,768  
Common stock issued to Board of Directors and Scientific Advisory Board that was earned in a previous period
    314,181       309,802  
Common stock issued to employees that was accrued for in a previous period, net of shares withheld for taxes
    929,552       845,745  
Common stock issued for royalties that was earned in a previous period
    81,273       81,954  



The accompanying notes are an integral part of these consolidated statements.


UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1.
BACKGROUND

Universal Display Corporation (the “Company”) is engaged in the research, development and commercialization of organic light emitting diode (“OLED”) technologies and materials for use in flat panel display, solid-state lighting and other product applications. The Company’s primary business strategy is to develop and license its proprietary OLED technologies to product manufacturers for use in these applications. In support of this objective, the Company also develops new OLED materials and sells those materials to product manufacturers. Through internal research and development efforts and relationships with entities such as Princeton University (“Princeton”), the University of Southern California (“USC”), the University of Michigan (“Michigan”), Motorola, Inc. (“Motorola”) and PPG Industries, Inc. (“PPG Industries”), the Company has established a significant portfolio of proprietary OLED technologies and materials (Notes 5 and 6).

2.
BASIS OF PRESENTATION

Interim Financial Information

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the Company’s financial position as of March 31, 2010, results of operations and cash flows for the three months ended March 31, 2010 and 2009. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2009.  The results of Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.

Management’s Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
Fair Value of Financial Instruments
 
Cash equivalents, accounts receivable, other current assets and accounts payable are reflected in the accompanying financial statements at fair value due to the short-term nature of those instruments. See Note 4 for a discussion of short-term investments and stock warrant liability.

Recent Accounting Pronouncements

In September 2009, the Financial Accounting Standards Board (“FASB”) issued guidance which will affect the revenue recognition accounting policies for transactions that involve multiple deliverables. The new guidance requires companies to allocate revenue in arrangements involving multiple deliverables based on the estimated selling price of each deliverable, even though those deliverables are not sold separately either by the company itself or other vendors. This new guidance eliminates the requirement that all undelivered elements have objective and reliable evidence of fair value before a company can recognize the portion of the overall arrangement fee that is attributable to items that already have been delivered. In the absence of vendor-specific objective evidence and third-party evidence for one or more elements in a multiple-element arrangement, companies will estimate the selling prices of those elements. The overall arrangement fee will be allocated to each element whether delivered or undelivered, based on their relative selling prices, regardless of whether those estimated selling prices are evidenced by vendor-specific objective evidence, third-party evidence of fair value or are based on the company’s judgment. The new guidance will be effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. However, early adoption is permitted. If a company elects early adoption and the period of adoption is not the beginning of its fiscal year, the requirements must be applied retrospectively to the beginning of the fiscal year. Retrospective application to prior years is permitted, but not required. In the initial year of application, companies are required to make qualitative and quantitative disclosures about the impact of the changes. In many
 
 
circumstances, the new guidance under these consensuses will require significant changes to a company’s revenue recognition policies and procedures, including system modifications. The Company does not expect this new guidance to have a material impact on its results of operations or financial position.

In January 2010, the FASB issued amended standards that require additional fair value disclosures. These amended standards require disclosures about inputs and valuation techniques used to measure fair value as well as disclosures about significant transfers, beginning in the first quarter of 2010.  Additionally, these amended standards require presentation of disaggregated activity within the reconciliation for fair value measurements using significant unobservable inputs (Level 3), beginning in the first quarter of 2011. The adoption of this new guidance did not have an impact on the Company’s results of operations or financial position.
 
In April 2010, the FASB issued guidance allowing the milestone method as an acceptable revenue recognition methodology when an arrangement includes substantive milestones. The guidance provides a definition of a substantive milestone and should be applied regardless of whether the arrangement includes single or multiple deliverables or units of accounting. The scope of this consensus is limited to the transactions involving milestones relating to research and development deliverables. The guidance includes enhanced disclosure requirements about each arrangement, individual milestones and related contingent consideration, information about substantive milestones and factors considered in the determination. The consensus is effective prospectively to milestones achieved in interim and annual reporting periods beginning after June 15, 2010. Early application and retrospective application are permitted. The Company does not expect this guidance to have a material impact on its results of operations or financial position.

3.
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company classifies its existing marketable securities as available-for-sale. These securities are, carried at fair market value, with unrealized gains and losses reported in shareholders’ equity. Gains or losses on securities sold are based on the specific identification method.

Short-term investments at March 31, 2010 and December 31, 2009 consisted of the following:

   
Amortized
   
Unrealized
   
Aggregate Fair
 
Investment Classification
 
Cost
   
Gains
   
(Losses)
   
Market Value
 
                         
March 31, 2010 –
                       
Certificates of deposit
  $ 9,342,981     $ 2,545     $ (8,200 )   $ 9,337,326  
Corporate Bonds
    18,960,240       3,584       (2,916 )     18,960,908  
U.S. Government bonds
    27,172,125             (3,007 )     27,169,118  
    $ 55,475,346     $ 6,129     $ (14,123 )   $ 55,467,352  
                                 
December 31, 2009 –
                               
Certificates of deposit
  $ 8,688,457     $ 1,633     $ (7,245 )   $ 8,682,845  
U.S. Government bonds
    32,458,981       31,140       (11 )     32,490,110  
    $ 41,147,438     $ 32,773     $ (7,256 )   $ 41,172,955  

All short-term investments held at March 31, 2010 will mature within one year.

4.
FAIR VALUE MEASUREMENTS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2010:

         
Fair Value Measurements, Using
 
   
Total carrying value as of March 31, 2010
   
Quoted prices in active markets (Level 1)
   
Significant other observable inputs
(Level 2)
   
Significant unobservable inputs
(Level 3)
 
Investments
  $ 55,467,352     $ 55,467,352     $     $  
Stock warrant liability
    3,006,922                   3,006,922  

 
The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2009:

         
Fair Value Measurements, Using
 
   
Total carrying value as of December 31, 2009
   
Quoted prices in active markets (Level 1)
   
Significant other observable inputs
(Level 2)
   
Significant unobservable inputs
(Level 3)
 
Investments
  $ 41,172,955     $ 41,172,955     $     $  
Stock warrant liability
    3,720,165                   3,720,165  

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification is determined based on the lowest level input that is significant to the fair value measurement.

The following table is a reconciliation of the changes in fair value of the Company’s stock warrant liability for the three months ended March 31, which has been classified in Level 3 in the fair value hierarchy:

   
2010
   
2009
 
             
Fair value of stock warrant liability, beginning of period
  $ 3,720,165     $  
                 
Cumulative effect of reclassification of stock warrant liability under Accounting Standards Codification (“ASC”) 815
          2,689,110  
                 
Unrealized gain for period
    (713,243 )     (173,242 )
                 
Fair value of stock warrant liability, end of period
  $ 3,006,922     $ 2,515,868  

The fair value of the stock warrant liability was determined using the Black-Scholes option pricing model with the following inputs at March 31:

   
2010
 
2009
Contractual life (years)
 
1.4
 
0.9-2.4
Expected volatility
 
74.1%
 
68.8-89.5%
Risk-free interest rate
 
0.7%
 
0.6-0.8%
Annual dividend yield
 
 

5.
RESEARCH AND LICENSE AGREEMENTS WITH PRINCETON, USC AND MICHIGAN

The Company funded OLED technology research at Princeton and, on a subcontractor basis, at USC, for 10 years under a Research Agreement executed with Princeton in August 1997 (the “1997 Research Agreement”).  The Principal Investigator conducting work under the 1997 Research Agreement transferred to Michigan in January 2006.  Following this, the 1997 Research Agreement was allowed to expire on July 31, 2007.

As a result of the transfer, the Company entered into a new Sponsored Research Agreement with USC to sponsor OLED technology research at USC and, on a subcontractor basis, Michigan.  This new Research Agreement (the “2006 Research Agreement”) was effective as of May 1, 2006, and had an original term of three years.  The 2006 Research Agreement superseded the 1997 Research Agreement with respect to all work being performed at USC and Michigan.  Payments under the 2006 Research Agreement are made to USC on a quarterly basis as actual expenses are incurred.  The Company incurred $2,155,570 in research and development expense for work performed under the 2006 Research Agreement during the original term, which ended on April 30, 2009.

Effective May 1, 2009, the Company amended the 2006 Research Agreement to extend the term of the agreement for an additional four years. Under the amendment, the Company is obligated to pay USC up to $7,456,294 for work actually performed during the extended term, which runs through April 30, 2013.  From May 1, 2009 through March 31, 2010, the Company incurred $796,679 in research and development expense for work performed under the amended 2006 Research Agreement.

 
On October 9, 1997, the Company, Princeton and USC entered into an Amended License Agreement (as amended, the “1997 Amended License Agreement”) under which Princeton and USC granted the Company worldwide, exclusive license rights, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of work performed by Princeton and USC under the 1997 Research Agreement.  Under this agreement, the Company is required to pay Princeton royalties for licensed products sold by the Company or its sublicensees.  For licensed products sold by the Company, the Company is required to pay Princeton 3% of the net sales price of these products.  For licensed products sold by the Company’s sublicensees, the Company is required to pay Princeton 3% of the revenues received by the Company from these sublicensees.  These royalty rates are subject to renegotiation for products not reasonably conceivable as arising out of the 1997 Research Agreement if Princeton reasonably determines that the royalty rates payable with respect to these products are not fair and competitive.

The Company is obligated under the 1997 Amended License Agreement to pay to Princeton minimum annual royalties.  The minimum royalty payment is $100,000 per year.  The Company accrued royalty expense in connection with this agreement of $68,392 and $44,363 for the three months ended March 31, 2010 and 2009, respectively.

The Company also is required under the 1997 Amended License Agreement to use commercially reasonable efforts to bring the licensed OLED technology to market.  However, this requirement is deemed satisfied if the Company invests a minimum of $800,000 per year in research, development, commercialization or patenting efforts respecting the patent rights licensed to the Company.

In connection with entering into the 2006 Research Agreement, the Company amended the 1997 Amended License Agreement to include Michigan as a party to that agreement effective as of January 1, 2006.  Under this amendment, Princeton, USC and Michigan have granted the Company a worldwide exclusive license, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of work performed under the 2006 Research Agreement.  The financial terms of the 1997 Amended License Agreement were not impacted by this amendment.

6.
EQUITY AND CASH COMPENSATION UNDER THE PPG INDUSTRIES AGREEMENTS

On October 1, 2000, the Company entered into a five-year Development and License Agreement (“Development Agreement”) and a seven-year Supply Agreement (“Supply Agreement”) with PPG Industries.  Under the Development Agreement, a team of PPG Industries scientists and engineers assisted the Company in developing its proprietary OLED materials and supplied the Company with these materials for evaluation purposes.  Under the Supply Agreement, PPG Industries supplied the Company with its proprietary OLED materials that were intended for resale to customers for commercial purposes.

On July 29, 2005, the Company entered into an OLED Materials Supply and Service Agreement with PPG Industries (the “OLED Materials Agreement”).  The OLED Materials Agreement superseded and replaced in their entireties the Development Agreement and Supply Agreement effective as of January 1, 2006, and extended the term of the Company’s relationship with PPG Industries through December 31, 2009.  Under the OLED Materials Agreement, PPG Industries continues to assist the Company in developing its proprietary OLED materials and supplying the Company with those materials for evaluation purposes and for resale to its customers.  On January 4, 2008, the term of the OLED Materials Agreement was extended for an additional three years, through December 31, 2011.

Under the OLED Materials Agreement, the Company compensates PPG Industries on a cost-plus basis for the services provided during each calendar quarter.  The Company is required to pay for some of these services in all cash and for other of the services through the issuance of shares of the Company’s common stock.  Up to 50% of the remaining services are payable, at the Company’s sole discretion, in cash or shares of the Company’s common stock, with the balance payable in all cash.  The actual number of shares of common stock issuable to PPG Industries is determined based on the average closing price for the Company’s common stock during a specified number of days prior to the end of each calendar half-year period ending on March 31 and September 30.  If, however, this average closing price is less than $6.00, the Company is required to compensate PPG Industries in all cash.

The Company is also required under the OLED Materials Agreement to reimburse PPG Industries for its raw materials and conversion costs for all development chemicals produced on behalf of the Company.

The Company issued 20,409 and 36,826 shares of the Company’s common stock to PPG Industries as consideration for services provided by PPG Industries under the OLED Materials Agreement during the three months ended March 31, 2010
 
 
and 2009, respectively. For these shares, the Company recorded $243,459 and $309,375 to research and development expense for the three months ended March 31, 2010 and 2009, respectively. Of the shares earned in the three months ended March 31, 2010, 17,446 shares were issued in April 2010.

The Company recorded a credit of $43,418 and an expense of $313,788 to research and development expense for the cash portion of the reimbursement of expenses to, and work performed by, PPG Industries for the three months ended March 31, 2010 and 2009, respectively.

7.
SHAREHOLDERS’ EQUITY

   
Series A
                     
Unrealized
             
   
Nonconvertible
               
Additional
   
(Loss) Gain on
         
Total
 
   
Preferred Stock
   
Common Stock
   
Paid-In
   
Available-for-
   
Accumulated
   
Shareholders’
 
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Sale Securities
   
Deficit
   
Equity
 
BALANCE, JANUARY 1, 2010
    200,000     $ 2,000       36,818,440     $ 368,184     $ 256,340,530     $ 25,517     $ (197,108,705 )   $ 59,627,526  
Exercise of common stock options and warrants (A)
                75,750       758       721,924                   722,682  
Stock-based employee compensation, net of shares withheld for taxes (B)
                637,978       6,379       854,077                   860,456  
Stock-based non-employee compensation
                195       2       40,846                   40,848  
Issuance of common stock to Board of Directors and Scientific Advisory Board (C)
                44,670       447       463,437                   463,884  
Issuance of common stock in connection with materials and license agreements (D)
                10,163       102       116,517                   116,619  
Issuance of common stock under an Employee Stock Purchase Plan
                6,263       63       62,596                   62,659  
Net loss
                                        (2,978,331 )     (2,978,331 )
Unrealized loss on available-for-sale securities
                                  (33,511 )           (33,511 )
                                                                 
Comprehensive loss
                                                            (3,011,842 )
                                                                 
BALANCE, MARCH 31, 2010
    200,000     $ 2,000       37,593,459     $ 375,935     $ 258,599,927     $ (7,994 )     (200,087,036 )   $ 58,882,832  
                                                                 

(A)
During the three months ended March 31, 2010, the Company issued 75,750 shares of common stock upon the exercise of common stock options and warrants, resulting in cash proceeds of $722,682.
(B)
Includes $1,513,710 (106,825 shares) that was accrued for in a previous period and charged to expense when earned, but issued in 2010, less shares withheld for taxes in the amount of $584,158 (41,225 shares).
(C)
Includes $314,181 (38,910 shares) that was earned in a previous period and charged to expense when earned, but issued in 2010.
(D)
The Company was required to pay Motorola royalties of $162,558 for the year ended December 31, 2009.  In March 2010, the Company issued to Motorola 7,200 shares of the Company’s common stock, valued at $81,273, and paid Motorola $81,285 in cash to satisfy this royalty obligation.




8.
STOCK-BASED COMPENSATION

The Company recognizes in its results of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and directors. The grant-date fair value of stock options is determined using the Black-Scholes valuation model. The fair value of share-based awards is recognized as compensation expense on a straight-line basis over the requisite service period, net of estimated forfeitures.  The Company relies primarily upon historical experience to estimate expected forfeitures and recognizes compensation expense on a straight-line basis from the date of the grant.  The Company issues new shares upon the respective exercise, grant or vesting of share-based awards, as applicable.

Equity Compensation Plan

In 1995, the Board of Directors of the Company adopted a Stock Option Plan (the “1995 Plan”), under which options to purchase a maximum of 500,000 shares of the Company’s common stock were authorized to be granted at prices not less than the fair market value of the common stock on the date of the grant, as determined by the Compensation Committee of the Board of Directors.  Through March 31, 2010, the Company’s shareholders have approved increases in the number of shares reserved for issuance under the 1995 Plan to 7,000,000, and have extended the term of the plan through 2015.  The 1995 Plan was also amended and restated in 2003, and is now called the Equity Compensation Plan.  The Equity Compensation Plan provides for the granting of incentive and nonqualified stock options, shares of common stock, stock appreciation rights and performance units to employees, directors and consultants of the Company.  Stock options are exercisable over periods determined by the Compensation Committee, but for no longer than 10 years from the grant date.

During the three months ended March 31, 2010, the Company did not grant any options to employees. The Company recorded as compensation expense related to the vesting of all employee stock options a charge of $22,232 and a credit of $3,796 for the three months ended March 31, 2010 and 2009, respectively.

During the three months ended March 31, 2010, the Company also granted to a non-employee options to purchase 10,000 shares of the Company’s common stock. These stock options vested immediately and have exercise prices of $8.56 and $9.44. The fair value of the options granted was $38,366, which was charged to research and development expense for the three months ended March 31, 2010.

During the three months ended March 31, 2010, the Company granted 602,569 shares of restricted stock to employees.  These shares of restricted stock had a fair value of $7,818,403 on the date of grant and will vest in equal increments annually over three to five years from the date of grant, provided that the grantee is still an employee of the Company on the applicable vesting date.

For the three months ended March 31, 2010 and 2009, the Company recorded compensation expenses related to the vesting of restricted stock awards previously granted to employees.  These expenses were charged to general and administrative expense in amounts of $295,815 and $241,636, and to research and development expense in amounts of $118,149 and $116,702, for the three months ended March 31, 2010 and 2009, respectively.

During the three months ended March 31, 2010, the Company also granted to employees 655 shares of common stock, which shares were issued and fully vested at the date of grant.  For the fair value of fully-vested shares that were issued, the Company recorded charges to research and development expense of $8,500 and $10,490 for the three months ended March 31, 2010 and 2009, respectively.

During the three months ended March 31, 2010, the Company granted to non-employees 195 shares of common stock, which shares were issued and fully vested at the date of grant.  For the fair value of fully-vested shares that were issued, the Company recorded charges to research and development expense of $2,482 and $1,998 for the three months ended March 31, 2010 and 2009, respectively.

In connection with all common stock issued to employees for the three months ended March 31, 2010, 78,767 shares of common stock with a fair value of $1,116,387 were withheld in satisfaction of tax withholding obligations.

For the three months ended March 31, 2010, the Company issued 5,760 shares of common stock to members of its Board of Directors as partial compensation for services performed.  For the fair value of shares issued to its Board of Directors, the Company recorded charges to general and administrative expense of $67,631 and $58,830 for the three months ended March 31, 2010 and 2009, respectively.

 
For the three months ended March 31, 2010, the Company granted a total of 16,936 shares of restricted stock to certain members of its Scientific Advisory Board.  These shares of restricted stock will vest and be issued in equal increments annually over three years from the date of grant, provided that the grantee is still engaged as a consultant of the Company on the applicable vesting date.  The Company recorded charges to research and development expense for the vesting of all restricted stock awards to its Scientific Advisory Board of $82,072 and $22,499 for the three months ended March 31, 2010 and 2009, respectively.

Employee Stock Purchase Plan

On April 7, 2009, the Board of Directors of the Company adopted an Employee Stock Purchase Plan (the “ESPP”).  The ESPP was approved by the Company’s shareholders and became effective on June 25, 2009.  The Company has reserved 1,000,000 shares of common stock for issuance under the ESPP.  Unless sooner terminated by the Board of Directors, the ESPP will expire when all reserved shares have been issued.

Eligible employees may elect to contribute to the ESPP through payroll deductions during consecutive three-month purchase periods, the first of which began on July 1, 2009.  Each employee who elects to participate will be deemed to have been granted an option to purchase shares of the Company’s common stock on the first day of the purchase period.  Unless the employee opts out during the purchase period, the option will automatically be exercised on the last day of the period, which is the purchase date, based on the employee’s accumulated contributions to the ESPP.  The purchase price will equal 85% of the lesser of the price per share of common stock on the first day of the period or the last day of the period.

Employees may allocate up to 10% of their base compensation to purchase shares of common stock under the ESPP; however, each employee may purchase no more than 12,500 shares on a given purchase date, and no employee may purchase more than $25,000 of common stock under the ESPP during a given calendar year.

For three months ended March 31, 2010, the Company issued 6,263 shares of its common stock under the ESPP, resulting in proceeds of $62,659. For the three months ended March 31, 2010, the Company recorded expenses of $5,975 to general and administrative expense and $11,490 to research and development expense related to the ESPP, which expenses equal the amount of the discount and the value of the look-back feature.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period.  Diluted net loss per common share reflects the potential dilution from the exercise or conversion of securities into common stock, the impact of unvested restricted stock awards and shares to be issued under the ESPP.  For the three months ended March 31, 2010 and 2009, the effects of the exercise of the combined outstanding stock options and warrants and unvested restricted stock awards of 4,379,049 and 4,429,182, respectively, and the impact of shares to be issued under the ESPP, which was minor, were excluded from the calculation of diluted EPS as the impact would have been antidilutive.

9.
COMMITMENTS AND CONTINGENCIES

Commitments

Under the 2006 Research Agreement with USC, the Company is obligated to make certain payments to USC based on work performed by USC under that agreement, and by Michigan under its subcontractor agreement with USC.  See Note 5 for further explanation.

Under the terms of the 1997 Amended License Agreement, the Company is required to make minimum royalty payments to Princeton.  See Note 5 for further explanation.

The Company is required under a license agreement with Motorola to pay royalties to Motorola based on gross revenues earned by the Company from its sales of OLED products or components, or from its OLED technology licensees, whether or not these revenues relate specifically to inventions claimed in the patent rights licensed from Motorola.  All royalty payments are payable, at the Company’s discretion, in either all cash or up to 50% in shares of the Company’s common stock and the remainder in cash.  The number of shares of common stock used to pay the stock portion of the royalty payment is calculated by dividing the amount to be paid in stock by the average daily closing price per share of the Company’s common stock over the 10 trading days ending two business days prior to the date the stock is issued. The Company accrued royalty expense in connection with this agreement of $49,168 and $36,067 for the three months ended March 31, 2010 and 2009, respectively.
 
 
Opposition to European Patent No. 0946958

On December 8, 2006, Cambridge Display Technology, Ltd. (“CDT”), which was acquired in 2007 by Sumitomo Chemical Company (“Sumitomo”), filed a Notice of Opposition to European Patent No. 0946958 (the “EP ‘958 patent”).  The EP ‘958 patent, which was issued on March 8, 2006, is a European counterpart patent to U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073.  These patents relate to the Company’s FOLED technology.  They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The European Patent Office (the “EPO”) conducted an Oral Hearing in this matter on October 6, 2009.  No representative from CDT attended the Oral Hearing.  At the conclusion of the Oral Hearing, the EPO panel announced its decision to reject the opposition and to maintain the patent as granted.  The minutes of the Oral Hearing were dispatched on October 27, 2009, and the EPO issued its official decision on November 26, 2009.

CDT filed an appeal to the EPO decision on January 25, 2010.  CDT timely filed its grounds for the appeal with the EPO on or about April 1, 2010.  The EPO has now set August 12, 2010 as the due date for the Company to file its reply to this appeal.  At this time, Company management continues to believe that the EPO decision will be upheld on appeal, though the Company cannot make any assurances of this result.

Opposition to European Patent No. 1449238

On March 8, 2007, Sumation Company Limited (“Sumation”), a joint venture between Sumitomo and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (the “EP ‘238 patent”).  The EP ‘238 patent, which was issued on November 2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406 and 7,537,844; and to pending U.S. patent application 12/434,259, filed on May 1, 2009.  These patents and this patent application relate to the Company’s PHOLED technology.  They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

Two other parties filed additional oppositions to the EP ‘238 patent just prior to the August 2, 2007 expiration date for such filings.  On July 24, 2007, Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim, Germany, filed a third Notice of Opposition to the EP ‘238 patent.  The EPO combined all three oppositions into a single opposition proceeding.

The EPO set a January 6, 2008 due date for the Company to file its response to the opposition.  The Company requested a two-month extension to file this response, and the Company subsequently filed its response in a timely manner.  The Company is still waiting for the EPO to notify it of the date of the oral hearing.  The Company is also waiting to see whether the other parties in the opposition file any additional documents, to which the Company may respond.

At this time, Company management cannot make any prediction as to the probable outcome of the opposition.  However, based on an analysis of the evidence presented to date, Company management continues to believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.

Invalidation Trial in Japan for Japan Patent No. 3992929

On April 19, 2010, the Company received a copy of a Notice of Invalidation Trial from the Japanese Patent Office (the “JPO”) for its Japan Patent No. 3992929 (the “JP ‘929 patent”), which was issued on August 3, 2007.  The request for the Invalidation Trial was filed by Semiconductor Energy Laboratory Co., Ltd., of Kanagawa, Japan.  The JP ‘929 patent is a Japanese counterpart patent, in part, to the above-noted EP ‘238 patent and to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406 and 7,537,844; and to pending U.S. patent application 12/434,259, filed on May 1, 2009.

The JPO has set a due date of July 15, 2010 for the Company to file its response to the evidence and arguments submitted with the request for the Invalidation Trial.  At this time, Company management cannot make any prediction as to the probable outcome of the Invalidation Trial.  The Company has not yet had an opportunity to study the evidence presented in the invalidation request.  However, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.

 
Opposition to European Patent No. 1394870

On about April 20, 2010, five European companies filed Notices of Opposition to European Patent No. 1394870 (the “EP ‘270 patent”).  The EP ‘270 patent, which was issued on July 22, 2009, is a European counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542 and 7,563,519; and to pending U.S. patent application 12/489,045, filed on June 22, 2009.  These patents and this patent application relate to the Company’s PHOLED technology.  They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.  The five companies are Merck Patent GmbH, of Darmstadt, Germany; BASF Schweitz AG of Basil, Switzerland; Osram GmbH of Munich, Germany; Siemens Aktiengesellschaft of Munich, Germany; and Koninklijke Philips Electronics N.V., of Eindhoven, The Netherlands.

The EPO has not yet set a due date for the Company to file its response to the oppositions.  At this time, Company management cannot make any prediction as to the probable outcome of the oppositions, which may be combined by the EPO into a single opposition proceeding.  The Company has not yet had an opportunity to study the evidence presented in the opposition documents.  However, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.

10.
CONCENTRATION OF RISK

Contract research revenue, which is included in developmental revenue in the accompanying statement of operations, of $1,131,902 and $895,586 for the three months ended March 31, 2010 and 2009, respectively, has been derived from contracts with United States government agencies. Revenues derived from contracts with government agencies represented 27% and 32% of consolidated revenue for the three months ended March 31, 2010 and 2009, respectively.

Two non-government customers accounted for approximately 48% and 40% of consolidated revenue for the three months ended March 31, 2010 and 2009, respectively. Accounts receivable from these customers were $1,039,570 at March 31, 2010.  Revenues from outside of North America represented 71% and 66% of consolidated revenue for the three months ended March 31, 2010 and 2009, respectively.

All chemical materials sold by the Company were purchased from one supplier.  See Note 6.

11.
INCOME TAXES

During the three months ended March 31, 2010, the Company sold approximately $3.8 million of its state-related income tax net operating losses (NOLs) and $194,088 of its research and development tax credits under the New Jersey Technology Tax Certificate Transfer Program and received proceeds of $464,162. The Company recorded these proceeds as an income tax benefit.

12.
SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

On March 18, 2010, the Compensation Committee and the Board of Directors of the Company approved and adopted the Universal Display Corporation Supplemental Executive Retirement Plan (the “SERP”). The SERP became effective as of April 1, 2010. The Company will record a non-current liability and accumulated other comprehensive loss relating to prior service cost under the SERP effective April 1, 2010, which is estimated to be approximately $5.6 million.  This amount is subject to finalization of actuarial estimates which are currently in process.


MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes above.

CAUTIONARY STATEMENT
CONCERNING FORWARD-LOOKING STATEMENTS

This discussion and analysis contains some “forward-looking statements.” Forward-looking statements concern our possible or assumed future results of operations, including descriptions of our business strategies and customer relationships. These
 
 
statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. These statements are based on assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances.

As you read and consider this discussion and analysis, you should not place undue reliance on any forward-looking statements. You should understand that these statements involve substantial risk and uncertainty and are not guarantees of future performance or results. They depend on many factors that are discussed further in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2009, as supplemented by any disclosures in Item 1A of Part II below. Changes or developments in any of these areas could affect our financial results or results of operations, and could cause actual results to differ materially from those contemplated in the forward-looking statements.

All forward-looking statements speak only as of the date of this report or the documents incorporated by reference, as the case may be. We do not undertake any duty to update any of these forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

OVERVIEW

We are a leader in the research, development and commercialization of organic light emitting diode, or OLED, technologies for use in flat panel display, solid-state lighting and other applications. Since 1994, we have been exclusively engaged, and expect to continue to be exclusively engaged, in funding and performing research and development activities relating to OLED technologies and materials, and in attempting to commercialize these technologies and materials. Our revenues are generated through contract research, sales of development and commercial chemicals, technology development and evaluation agreements and license fees and royalties. In the future, we anticipate that revenues from licensing our intellectual property will become a more significant part of our revenue stream.

While we have made significant progress over the past few years developing and commercializing our PHOLED and other OLED technologies and materials, we have incurred significant losses and will likely continue to do so until our OLED technologies and materials become more widely adopted by product manufacturers. We have incurred significant losses since our inception, resulting in an accumulated deficit of $200,087,036 as of March 31, 2010.

We anticipate fluctuations in our annual and quarterly results of operations due to uncertainty regarding, among other factors:

·
the timing of our receipt of license fees and royalties, as well as fees for future technology development and evaluation;
   
·
the timing and volume of sales of our OLED materials for both commercial usage and evaluation purposes;
   
·
the timing and magnitude of expenditures we may incur in connection with our ongoing research and development activities; and
   
·
the timing and financial consequences of our formation of new business relationships and alliances.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2010 Compared to Three Months Ended March 31, 2009

We had an operating loss of $4,224,332 for the three months ended March 31, 2010, compared to an operating loss of $5,993,599 for the three months ended March 31, 2009. The decrease in operating loss was due to:

·
an increase in revenue of $1,412,792; and

·
a decrease in operating expenses of $356,474.

We had a net loss of $2,978,331 (or $0.08 per basic and diluted share) for the three months ended March 31, 2010, compared to a net loss of $5,569,599 (or $0.15 per basic and diluted share) for the three months ended March 31, 2009. The decrease in net loss was primarily due to:

 
·
an increase in gain on stock warrant liability of $540,001;

·
an income tax benefit of $464,162; and

·
a decrease in total operating loss of $1,769,266.

Our revenues were $4,246,650 for the three months ended March 31, 2010, compared to $2,833,858 for the three months ended March 31, 2009.

Commercial revenue increased to $1,830,147 for the three months ended March 31, 2010, compared to $1,369,137 for the three months ended March 31, 2009.  Commercial revenue relates to the incorporation of our OLED technologies and materials into our customers’ commercial products, and includes commercial chemical revenue, royalty and license revenues, and commercialization assistance revenue.  The increase in commercial revenue was primarily due to the following:

·
an increase of $287,698 in royalty revenue, which mainly represented royalties received under our patent license agreement with Samsung SMD Co., Ltd. (“Samsung SMD”);

·
an increase of $106,760 in license fees, principally due to a license agreement we entered into with Showa Denko K.K. in December 2009 and license fees received in connection with increased sales of our materials to a customer; and

·
an increase of $42,235 in commercial chemical revenue.

We cannot accurately predict how long our material sales to particular customers will continue, as they frequently update and alter their product offerings in response to market demands. Continued sales of our OLED materials to these customers will depend on several factors, including pricing, availability, continued technical improvement and competitive product offerings.
 
Developmental revenue increased to $2,416,503 for the three months ended March 31, 2010, compared to $1,464,721 for the three months ended March 31, 2009.  Developmental revenue relates to OLED technology and material development and evaluation activities for which we are paid, and includes contract research revenue, development chemical revenue and technology development revenue. The increase in developmental revenue was primarily due to the following:

·
an increase of $745,822 in development chemical revenue, mainly due to increased purchases of development chemicals by a customer; and

·
an increase of $236,316 in contract research revenue, principally to the timing of work performed and costs incurred in connection with existing government contracts, as well as an overall increase in value of our government contracts.

Cost of chemicals sold increased to $460,786 for the three months ended March 31, 2010, compared to $170,987 for the three months ended March 31, 2009, based on the aforementioned increase in chemical sales.

We incurred research and development expenses of $4,466,631 for the three months ended March 31, 2010, compared to $5,219,062 for the three months ended March 31, 2009. The decrease was mainly due to:

·
decreased costs of $941,820 incurred under our agreement with PPG Industries; and

·
decreased costs of $91,649 under our sponsored research agreements; partially offset by

·
increased employee costs of $215,596 and an overall increase in other operating costs of $65,442.

Selling, general and administrative expenses were $2,642,246 for the three months ended March 31, 2010, compared to $2,622,945 for the three months ended March 31, 2009. Selling, general and administrative expenses remained relatively consistent over these corresponding periods.

Interest income decreased to $75,655 for the three months ended March 31, 2010, compared to $253,400 for the three months ended March 31, 2009.  The decrease was mainly attributable to decreased rates of return on investments during three months ended March 31, 2010, compared to rates of return during 2009. Due to current market conditions, we anticipate that these lower rates of return will continue for the foreseeable future.

 
At March 31, 2010, we had outstanding warrants to purchase 744,452 shares of common stock, which contain a “down-round” provision requiring liability classification.  The change in fair value of these warrants as well as the expiration of warrants with a similar provision during the period resulted in a $713,243 non-cash gain on our statement of operations for the three months ended March 31, 2010, compared to a $173,242 non-cash gain for the three months ended March 31, 2009.  We will continue to report the warrants as a liability, with changes in fair value recorded in the statement of operations, until such time as these warrants are exercised or expire.

During the three months ended March 31, 2010, we sold approximately $3.8 million of our state-related income tax net operating losses (NOLs) and $194,088 of our research and development tax credits under the New Jersey Technology Tax Certificate Transfer Program.  We received proceeds of $464,162 from our sale of these NOLs and research and development tax credits, and we recorded these proceeds as an income tax benefit.  In past years, we completed our sales of state-related tax NOLs during the fourth quarter of the year.

Liquidity and Capital Resources

As of March 31, 2010, we had cash and cash equivalents of $7,553,643 and short-term investments of $55,467,352, for a total of $63,020,995. This compares to cash and cash equivalents of $22,701,126 and short-term investments of $41,172,955, for a total of $63,874,081, as of December 31, 2009. The decrease in cash and cash equivalents and short-term investments of $853,086 was primarily due to the usage of cash in operations and financing activities.

Cash used in operating activities was $442,848 for the three months ended March 31, 2010, compared to $4,505,171 for the same period in 2009. The decrease in cash used in operating activities was mainly due to the following:

·
a decrease in net loss of $2,064,384, which amount excludes the impact of non-cash items;
   
·
the receipt of $925,000 in cash payments during the three months ended March 31, 2010 for license rights and as advanced payments under a government contract, compared to $66,667 in corresponding cash payments received during the three months ended March 31, 2009;
   
·
the impact of the timing of payment of accounts payable and accrued expenses of $776,653; and
   
·
the impact of the timing of receipt of accounts receivable of $307,872.

Cash used in investing activities was $14,373,589 for the three months ended March 31, 2010, compared to $16,920,046 for the same period in 2009. The decrease is mainly due to the use of cash to finance operations.

Cash used in financing activities was $331,046 for the three months ended March 31, 2010, compared to $831,877 for the same period in 2009. In the first three months of 2010, we used $1,116,387 for the payment of withholding taxes related to stock based compensation, compared $831,877 used for corresponding payments in the first three months of 2009. This was partially offset by the receipt of proceeds of $722,682 from the exercise of options and warrants to purchase shares of our common stock during the first three months of 2010 and $62,659 in proceeds related to our ESPP.

Working capital was $53,480,575 as of March 31, 2010, compared to $53,663,617 as of December 31, 2009.  We anticipate, based on our internal forecasts and assumptions relating to our operations (including, among others, assumptions regarding our working capital requirements, the progress of our research and development efforts, the availability of sources of funding for our research and development work, and the timing and costs associated with the preparation, filing, prosecution, maintenance, defense and enforcement of our patents and patent applications), that we have sufficient cash, cash equivalents and short-term investments to meet our obligations for at least the next 12 months.

We believe that potential additional financing sources for us include long-term and short-term borrowings, public and private sales of our equity and debt securities and the receipt of cash upon the exercise of warrants and options. It should be noted, however, that additional funding may be required in the future for research, development and commercialization of our OLED technologies and materials, to obtain, maintain and enforce patents respecting these technologies and materials, and for working capital and other purposes, the timing and amount of which are difficult to ascertain. There can be no assurance that additional funds will be available to us when needed, on commercially reasonable terms or at all , particularly in the current economic environment.
 
 
Critical Accounting Policies

Refer to our Annual Report on Form 10-K for the year ended December 31, 2009, for a discussion of our critical accounting policies.  There have been no changes in critical accounting policies to date in 2010.

Contractual Obligations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2009, for a discussion of our contractual obligations.  There have been no changes in our contractual obligations to date in 2010.

Off-Balance Sheet Arrangements

Refer to our Annual Report on Form 10-K for the year ended December 31, 2009, for a discussion of off-balance sheet arrangements.  As of March 31, 2010, we had no off-balance sheet arrangements.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not utilize financial instruments for trading purposes and hold no derivative financial instruments, other financial instruments or derivative commodity instruments that could expose us to significant market risk other than our short-term investments and our stock warrant liability disclosed in Note 4 to the consolidated financial statements included herein. We invest in investment grade financial instruments to reduce our exposure.  Our primary market risk exposure with regard to financial instruments is to changes in interest rates, which would impact interest income earned on investments.

We record as a liability the fair value of warrants to purchase 744,452 shares of our common stock.  The fair value of the stock warrant liability is determined using the Black-Scholes option valuation model and is therefore sensitive to changes in the stock price and volatility of our common stock.  Our primary market risk exposure to the stock warrant liability is to changes in the stock price, which would impact the valuation of the stock warrant liability. Increases in our stock price or the expected volatility of our common stock would increase the fair value of the stock warrant liability and therefore result in an additional loss on the statement of operations. Decreases in these items would decrease the fair value of the stock warrant liability and therefore result in an additional gain on the statement of operations.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2010. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of the end of the period covered by this report, are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. However, a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended March 31, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 
PART II – OTHER INFORMATION

LEGAL PROCEEDINGS

Opposition to European Patent No. 0946958

On December 8, 2006, Cambridge Display Technology, Ltd. (“CDT”), which was acquired in 2007 by Sumitomo Chemical Company (“Sumitomo”), filed a Notice of Opposition to European Patent No. 0946958 (the “EP ‘958 patent”).  The EP ‘958 patent, which was issued on March 8, 2006, is a European counterpart patent to U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073.  These patents relate to our FOLED technology.  They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

The European Patent Office (the “EPO”) conducted an Oral Hearing in this matter on October 6, 2009.  No representative from CDT attended the Oral Hearing.  At the conclusion of the Oral Hearing, the EPO panel announced its decision to reject the opposition and to maintain the patent as granted.  The minutes of the Oral Hearing were dispatched on October 27, 2009, and the EPO issued its official decision on November 26, 2009.

CDT filed an appeal to the EPO decision on January 25, 2010.  CDT timely filed its grounds for the appeal with the EPO on or about April 1, 2010.  The EPO has now set August 12, 2010 as the due date for filing our reply to this appeal.  At this time, we continue to believe that the EPO decision will be upheld on appeal, though we cannot make any assurances of this result.

Opposition to European Patent No. 1449238

On March 8, 2007, Sumation Company Limited (“Sumation”), a joint venture between Sumitomo and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (the “EP ‘238 patent”).  The EP ‘238 patent, which was issued on November 2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406 and 7,537,844; and to pending U.S. patent application 12/434,259, filed on May 1, 2009.  These patents and this patent application relate to our PHOLED technology.  They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

Two other parties filed additional oppositions to the EP ‘238 patent just prior to the August 2, 2007 expiration date for such filings.  On July 24, 2007, Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim, Germany, filed a third Notice of Opposition to the EP ‘238 patent.  The EPO combined all three oppositions into a single opposition proceeding.

The EPO set a January 6, 2008 due date for us to file our response to the opposition.  We requested a two-month extension to file this response, and we subsequently filed our response in a timely manner.  We are still waiting for the EPO to notify us of the date of the oral hearing.  We are also waiting to see whether the other parties in the opposition file any additional documents, to which we may respond.

At this time, we cannot make any prediction as to the probable outcome of the opposition.  However, based on an analysis of the evidence presented to date, we continue to believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.

Invalidation Trial in Japan for Japan Patent No. 3992929

On April 19, 2010, we received a copy of a Notice of Invalidation Trial from the Japanese Patent Office (the “JPO”) for our Japan Patent No. 3992929 (the “JP ‘929 patent”), which was issued on August 3, 2007.  The request for the Invalidation Trial was filed by Semiconductor Energy Laboratory Co., Ltd., of Kanagawa, Japan.  The JP ‘929 patent is a Japanese counterpart patent, in part, to the above-noted EP ‘238 patent and to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406 and 7,537,844; and to pending U.S. patent application 12/434,259, filed on May 1, 2009.

The JPO has set a due date of July 15, 2010 for us to file our response to the evidence and arguments submitted with the request for the Invalidation Trial.  At this time, we cannot make any prediction as to the probable outcome of the Invalidation Trial.  We have not yet had an opportunity to study the evidence presented in the invalidation request.  However, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.
 
 
Opposition to European Patent No. 1394870

On about April 20, 2010, five European companies filed Notices of Opposition to European Patent No. 1394870 (the “EP ‘270 patent”).  The EP ‘270 patent, which was issued on July 22, 2009, is a European counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542 and 7,563,519; and to pending U.S. patent application 12/489,045, filed on June 22, 2009.  These patents and this patent application relate to our PHOLED technology.  They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.  The five companies are Merck Patent GmbH, of Darmstadt, Germany; BASF Schweitz AG of Basil, Switzerland; Osram GmbH of Munich, Germany; Siemens Aktiengesellschaft of Munich, Germany; and Koninklijke Philips Electronics N.V., of Eindhoven, The Netherlands.

The EPO has not yet set a due date for us to file our response to the oppositions.  At this time, we cannot make any prediction as to the probable outcome of the oppositions, which may be combined by the EPO into a single opposition proceeding.  We have not yet had an opportunity to study the evidence presented in the opposition documents.  However, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.

RISK FACTORS

There have been no material changes to the risk factors previously discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2009.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuance of Unregistered Shares

During the quarter ended March 31, 2010, we issued an aggregate of 20,000 unregistered shares of our common stock upon the exercise of outstanding warrants. The warrants had an exercise price of $12.39 per share. All of the shares were issued in reliance on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended.

Withholding of Shares to Satisfy Tax Liabilities

During the quarter ended March 31, 2010, we acquired 802 shares of common stock through transactions related to the vesting of restricted share awards previously granted to certain employees. Upon vesting, the employees turned in shares of common stock in amounts sufficient to pay their minimum statutory tax withholding at rates required by the relevant tax authorities.

The following table provides information relating to the shares we received during the first quarter of 2010.

Period
 
Total Number of Shares Purchased
   
Weighted Average Price Paid per Share
   
Total Number of Shares Purchased as Part of Publicly Announced Program
   
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
 
January 1 – January 31
        $       n/a       --  
February 1 – February 28
    201       10.99       n/a       --  
March 1 – March 31
    601       11.67       n/a       --  
Total
    802     $ 11.50       n/a       --  

DEFAULTS UPON SENIOR SECURITIES

None.

REMOVED AND RESERVED


OTHER INFORMATION

None.

 
EXHIBITS

The following is a list of the exhibits included as part of this report.  Where so indicated by footnote, exhibits that were previously included are incorporated by reference.  For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated parenthetically, together with a reference to the filing indicated by footnote.

Exhibit
   
Number
 
Description
     
10.1*
 
Amendment No. 3 to the Commercial Supply Agreement between the registrant and LG Display Co., Ltd., dated as of March 10, 2010
     
10.2* +
 
Universal Display Corporation Supplemental Executive Retirement Plan+
     
10.3* +
 
Universal Display Corporation Equity Retention Agreement with Steven V. Abramson+
     
10.4* +
 
Universal Display Corporation Equity Retention Agreement with Sidney D. Rosenblatt+
     
31.1*
 
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
     
31.2*
 
Certifications of Sidney D.  Rosenblatt, Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
   
32.1**
 
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C.  Section 1350.  (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.  Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
     
32.2**
 
Certifications of Sidney D. Rosenblatt, Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C.  Section 1350.  (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.  Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

*
 
Filed herewith.
**
 
Furnished herewith.
+
 
Compensatory plan or arrangement.
 
 
Note: Any of the exhibits listed in the foregoing index not included with this report may be obtained, without charge, by writing to Mr. Sidney D. Rosenblatt, Corporate Secretary, Universal Display Corporation, 375 Phillips Boulevard, Ewing, New Jersey 08618.


 
21

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized:


UNIVERSAL DISPLAY CORPORATION



Date: May 10, 2010
By:     /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer

 


AMENDMENT #3
 
to the
 
COMMERCIAL SUPPLY AGREEMENT
(originally effective May 23, 2007)
 
by and between
 
LG DISPLAY CO., LTD. (“LGD”) - formerly named LG.PHILIPS LCD CO., LTD.
 
and
 
UNIVERSAL DISPLAY CORPORATION (“UDC”)


This Amendment #3 shall amend and modify, to the extent of any inconsistency, the provisions of the above-referenced Commercial Supply Agreement, as previously amended effective as of June 30, 2008, and again effective as of June 30, 2009 (the “Agreement”).  This Amendment #3 shall be effective as of December 31, 2009.

1.           Article 9.1 of the Agreement is hereby amended to extend the term of the Agreement for six (6) additional months, through June 30, 2010.

2.           Except as set forth in this Amendment #3, all other terms and conditions of the greement shall remain in full force and effect.

IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this Amendment #3 to be executed by their duly authorized representatives:


LG DISPLAY CO., LTD.
 
UNIVERSAL DISPLAY CORPORATION
         
By:
/s/ Byung Chul Ahn
 
By:
/s/ Steven V. Abramson
         
Name:
Byung Chul Ahn
 
Name:
Steven V. Abramson
         
Title:
Vice President
 
Title:
President
         
Date:
Feb 19, 2010
 
Date:
March 10, 2010

 
 
 

Universal Display Corporation
 
Supplemental Executive Retirement Plan
 
Universal Display Corporation (“UDC”) hereby adopts a nonqualified defined benefit pension plan known as the Universal Display Corporation Supplemental Executive Retirement Plan (the “Plan”), effective as of April 1, 2010 (the “Effective Date”).
 
The principal purposes of the Plan are to provide certain key employees of UDC and its subsidiaries (collectively the “Company”) with retirement benefits that supplement other benefits that may be available to them under the terms of tax-qualified plans or otherwise, and to encourage the continued employment of such individuals with the Company and its subsidiary, UDC, Inc.
 
1.   Definitions .
 
(a)   Beneficiary ” means the person or entity designated in writing, on a form filed with the Company, as the beneficiary of payments that are to be made after a Participant’s death under the Plan.  If no designated Beneficiary is living or in existence at the date on which a payment is to be made, the Beneficiary shall be the personal representative of the Participant’s estate.
 
(b)   Board ” means the Board of Directors of UDC.
 
(c)   Cause ” means (i) the Participant materially breaches a written non-competition, non-solicitation or confidentiality agreement between the Participant and the Company and the Participant fails to cure the breach (if such breach is curable) within thirty (30) days after receiving written notice from the Company of the breach, (ii) the Participant commits an act of dishonesty, fraud, embezzlement or theft in connection with his duties or in the course of the Participant’s employment with the Company, (iii) the Participant is convicted of a felony or a crime of moral turpitude with respect to actions taken during employment with the Company, or (iv) the Participant engages in actions that are materially detrimental to the Company, including without limitation any actions that result in a material restatement of the financial statements of the Company.
 
(d)   Change in Control ” means the occurrence of any of the following:
 
(i)   if any Person or affiliated group of Persons (other than in their capacities as trustees of a trust existing on the Effective Date or any successor trust having the same beneficiaries) first become the “beneficial owners” (as defined in Rule 13d-3 under the Securities Exchange Act), directly or indirectly, of securities of UDC (not including in the securities beneficially owned by such Persons any securities acquired directly from UDC or its affiliates) representing thirty percent (30%) or more of either the then-outstanding shares of stock of UDC or the combined voting power of UDC’s then-outstanding securities;
 
(ii)   if, during any period of twenty-four (24) consecutive months during the existence of the Plan commencing on or after the Effective Date, the individuals who, at the beginning of such period, constitute the Board (the “Incumbent Directors”) cease for any
 

 
 

 

(iii)   reason other than death to constitute at least a majority thereof; provided that a director who was not a director at the beginning of such twenty-four (24) month (or shorter) period shall be deemed to have satisfied such requirement (and be an Incumbent Director) if such director was elected by, or on the recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually (because they were directors at the beginning of such twenty-four (24) month (or shorter) period) or by prior operation of this clause (ii);
 
(iv)   the consummation of a merger or consolidation of UDC with any other corporation other than (A) a merger or consolidation that would result in the voting securities of UDC outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least fifty percent (50%) of the combined voting power of the voting securities of UDC or such surviving entity or any parent outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected to implement a recapitalization of UDC (or a similar transaction) in which no Person or group of affiliated Persons (other than in their capacities as trustees of a trust existing on the Effective Date or any successor trust having the same beneficiaries) first become the “beneficial owners” (as defined in Rule 13d-3 under the Securities Exchange Act), directly or indirectly, of securities of UDC (not including in the securities beneficially owned by such Persons any securities acquired directly from UDC or its affiliates) representing thirty percent (30%) or more of either the then-outstanding shares of stock of UDC or the combined voting power of UDC’s then-outstanding securities;
 
(v)   the stockholders of UDC approve a plan of complete liquidation or dissolution of UDC, or there is consummated an agreement for the sale or disposition by UDC of all or substantially all of UDC’s assets, other than a sale or disposition by UDC of all or substantially all of UDC’s assets to an entity, at least fifty percent (50%) of the combined voting power of the voting securities of which is owned by Persons in substantially the same proportion as their ownership of UDC immediately prior to such sale; or
 
(vi)   any Person has consummated a tender offer or exchange for voting stock of UDC and, directly or indirectly, has become (in one or  more transactions) the “beneficial owner” of securities of UDC representing thirty percent (30%) or more of the voting power of the then outstanding shares of stock of UDC.
 
(e)   Code ” means the Internal Revenue Code, as amended from time to time.
 
(f)   Committee ” means the Compensation Committee of the Board.
 
(g)   ERISA ” means the Employee Retirement Income Security Act of 1974, as amended, and any successor act thereto.
 
(h)   Participant ” means an employee of the Company who is a “management or highly compensated employee” within the meaning of Sections 201, 301 and 401 of ERISA and is selected by the Committee to receive benefits under the Plan, as provided in Article 2 below.
 

 
-2-

 

(i)   Person ” means any corporation, partnership, limited liability company, joint venture, other entity or natural person.
 
(j)   Schedule of Retirement Benefits ” means the schedule of Participants and SERP benefits attached hereto as Exhibit A, and, if applicable, Exhibit B, as amended by the Committee or the Board from time to time.
 
(k)   Years of Service ” means a Participant’s full years of continuous service with the Company.
 
2.   Participants .
 
(a)   Eligibility .  Only those employees of the Company who are designated as eligible to participate in the Plan on the Schedule of Retirement Benefits shall be eligible for benefits hereunder.
 
(b)   Participation .  The Committee, acting in its discretion, may designate any eligible employee as a Participant under this Plan, and may designate any conditions applicable to any such Participant.  Such designation shall be in writing and shall be effective as of the date contained therein.  Participation in the Plan is terminable by the Committee, in its discretion, upon written notice to the Participant, and termination shall be effective as of the date contained therein, but in no event earlier than the date of such notice, provided that no such termination shall (except as provided in Section 3(e)) reduce or adversely affect any Participant’s rights to benefits previously accrued and vested hereunder without the consent of the Participant.
 
3.   Amount, Form and Payment of Benefits; Restrictions on Benefits .
 
(a)   Normal Retirement Benefit .  Subject to the terms of this Plan, a Participant who earns a vested benefit under the Plan shall be entitled to receive an annual SERP benefit as set forth in the Schedule of Retirement Benefits.
 
(b)   Form of Benefit .  The benefit payable to a Participant shall be paid at the time and in the manner set forth in the Schedule of Retirement Benefits.
 
(c)   Vesting .  Each Participant shall become vested in his or her benefits under the Plan when the Participant becomes entitled to receive such benefits as provided in the Schedule of Retirement Benefits.
 
(d)   Compliance With Section 409A of the Code .  This Plan is intended to comply with section 409A of the Code and its corresponding regulations, and payments may only be made under this Plan upon an event and in a manner permitted by section 409A, to the extent applicable.  Notwithstanding anything in this Plan to the contrary, if required by section 409A, if a Participant is considered a “specified employee” for purposes of section 409A and if payment of any amounts under this Plan is required to be delayed for a period of six months after separation from service pursuant to section 409A, payment of such amounts shall be delayed as required by section 409A, and the accumulated amounts shall be paid in a lump sum payment within 10 days after the end of the six-month period.  If the Participant dies during the postponement period prior to the payment of benefits, the amounts withheld on account of
 

 
-3-

 

(e)   section 409A shall be paid to the personal representative of the Participant’s estate within 60 days after the date of the Participant’s death.  Payments to be made upon a “termination of employment” or “separation from service” under this Plan may only be made upon a “separation from service” under section 409A.  In no event may the Participant, directly or indirectly, designate the calendar year of a payment.
 
(f)   Forfeiture . All benefits to any Participant hereunder, whether or not previously accrued or vested, shall be subject to immediate forfeiture in their entirety, and no further benefits shall be paid, in the event that the Participant’s employment is terminated for Cause or in the event the Company determines that the Participant has engaged in conduct that would constitute Cause at any time during or after employment with the Company.  A Participant’s benefits shall also be forfeited if the Participant’s employment terminates for any reason before benefits under the Plan are vested.
 
4.   Administration .
 
(a)   Authority of the Committee .  This Plan shall be administered by the Committee.  Subject to the provisions of the Plan, the Committee shall have the sole discretionary authority to make, amend, interpret, and enforce all appropriate rules and regulations for the administration of this Plan, and to decide or resolve any and all questions, including interpretations of this Plan, as may arise in connection with implementation of this Plan.  Notwithstanding the foregoing, the Company shall act, or designate an affiliate to act, as the plan administrator for purposes of any filings with any governmental entity or in the event claims for benefits are made by any Participant.
 
(b)   Agents .  In the administration of this Plan, the Committee may, from time to time, employ agents and delegate to such agents such administrative duties as it deems advisable and allowable under the terms of the Plan.
 
(c)   Decisions Binding .  Any decision or action of the Committee with respect to any question arising out of or in connection with the administration, interpretation, and application of this Plan, or any rules or guidelines made in connection with this Plan, shall be final and conclusive, and shall be binding upon all persons and entities having any interest in this Plan.  All benefits under the Plan shall be conditional upon the Participant’s acknowledgement, by acceptance of participation in the Plan, that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her spouse or beneficiaries and any other person having or claiming an interest under the Plan.
 
(d)   Indemnity of Committee .  The Company shall indemnify and hold harmless the Committee and its individual members, along with any other committee that may be established to administer the Plan pursuant to Section 4(a) above, including any individual members thereof, against any and all claims, losses, damages, expenses or liabilities arising from any action or failure to act with respect to this Plan, including reasonable attorneys’ fees and costs.
 

 
-4-

 

(e)   Cost of Administration .  The Company shall bear, or cause one of its affiliates to bear, all costs, expenses and obligations associated with the administration of this Plan.
 
(f)   Claims .
 
(i)   A Participant or a Participant’s Beneficiary or spouse may file a written claim for benefits under the Plan with the Committee if he or she believes that he or she is entitled to receive benefits under the Plan but is not receiving benefits under the Plan, or if he or she is receiving benefits under the Plan, but disputes the amount and/or form of benefits received.  Such written claim for benefits shall set forth the nature of the claim and/or dispute, and set forth all facts and circumstances known to him or her that are relevant to the claim.
 
(ii)   If, pursuant to the provisions of the Plan, the Company denies the claim of the Participant or the Participant’s Beneficiary or spouse for benefits under the Plan, the Company shall provide written notice, within forty-five (45) days after receipt of the claim, setting forth in a manner reasonably designed to be understood by the claimant:
 
(A)   the specific reasons for such denial;
 
(B)   the specific reference to the Plan provisions on which the denial is based;
 
(C)   a description of any additional material or information necessary to perfect the claim and an explanation of why such material or information is needed; and
 
(D)   an explanation of the Plan’s claim review procedure and the time limitations of this subsection applicable thereto.
 
(iii)   The Participant or the Participant’s Beneficiary or spouse whose claim for benefit has been denied may request review by the Company of the denied claim by notifying the Company in writing within thirty (30) days after receipt of the notification of claim denial.  As part of said review procedure, the claimant or the claimant’s authorized representative may review pertinent documents and submit issues and comments to the Company in writing.  The Company shall render its decision to the claimant in writing in a manner reasonably designed to be understood by the claimant not later than thirty (30) days after receipt of the request for review, unless special circumstances require an extension of time, in which case decision shall be rendered as soon after the 60-day period as practicable, but not later than sixty (60) days after receipt of the request for review.  The decision on review shall state the specific reasons therefor and the specific Plan reference on which it is based.
 
5.   Amendment and Termination .
 
(a)   The Company hereby reserves the right to amend, modify, or terminate the Plan (and the Schedule of Retirement Benefits) at any time, and from time to time, by action of the Committee or the Board.  Except as described below in this Article 5, no such amendment or
 

 
-5-

 

(b)   termination shall in any material manner reduce or adversely affect any Participant’s rights to previously accrued and vested benefits hereunder without the consent of such Participant.
 
(c)   The Company may terminate the Plan and commence termination payout for all Participants, to the extent consistent with section 409A of the Code, or remove certain employees as Participants, if it is determined by the United States Department of Labor or a court of competent jurisdiction that the Plan constitutes an employee pension benefit plan within the meaning of Section 3(2) of ERISA which is not exempt from the provisions of Parts 2, 3 and 4 of Title I of ERISA; provided, however, that if the Plan is terminated pursuant to this sentence, then all Participants shall be deemed to be vested in the benefits described in Article 3 as of the date immediately preceding such termination, and such benefits shall be paid in accordance with section 409A of the Code.
 
6.   Miscellaneous .
 
(a)   Unfunded Plan .  This Plan is intended to be a nonqualified, unfunded plan maintained primarily to provide deferred compensation benefits to a Participant who falls within a select group of “management or highly compensated employees” within the meaning of Sections 201, 301 and 401 of ERISA.  Such status shall not be adversely affected by the establishment of any trust pursuant to Section 6(d) below.
 
(b)   Unsecured General Creditor .  Each Participant and his or her Beneficiary, spouse, heirs, successors and assigns shall have no secured legal or equitable rights, interests or claims in any property or assets of the Company, nor shall any such persons have any rights, interests or claims in any life insurance policies, annuity contracts or the proceeds therefrom owned or which may be acquired by the Company.  Except as provided in Section 6(d) below, such policies, annuity contracts or other assets of the Company shall not be held under any trust for the benefit of a Participant, his or her beneficiaries, heirs, successors or assigns, or held, in any way, as collateral security for the fulfilling of any obligations of the Company under this Plan.  Any and all of the Company’s assets and policies shall be, and shall remain for purposes of this Plan, the general, unpledged and unrestricted assets of such entities.  All obligations of the Company under this Plan shall be that of an unfunded and unsecured promise to pay money in the future.
 
(c)   Supplemental Benefits .  The Plan is intended to be a supplemental source of Company-paid retirement benefits for Participants and not the sole source of such benefits.  The benefits payable hereunder shall, therefore, not be subject to any reduction because of benefits that may be paid or otherwise provided to a Participant, except to the extent that an offset is explicitly provided for in a contractual arrangement with a particular Participant and except as otherwise provided herein.
 
(d)   Trust Fund .
 
(i)   At the Committee’s discretion, the Company may establish or cause the establishment of one or more grantor “rabbi” trusts, with such trustees as the Committee may approve, for the purpose of providing for the payment of benefits under this
 

 
-6-

 

(ii)   Plan.  Such trust or trusts may be irrevocable, but the assets thereof shall be subject to the claims of the Company’s general creditors.  To the extent any benefits provided under this Plan are actually paid from any such trust, the Company shall have no further obligation with respect thereto, but to the extent not so paid, such benefits shall remain the obligation of, and shall be paid by, the Company.
 
(iii)   Notwithstanding the foregoing, in the event there is a Change in Control of the Company, the Company shall, if it has not previously done so, establish or cause to be established an irrevocable grantor “rabbi” trust or shall cause any trust previously established pursuant to this Section 6(d) to become irrevocable, and, subject to compliance with section 409A of the Code, shall contribute to such irrevocable trust at or before the date of the event that constitutes a Change in Control of the Company (or as soon as practicable thereafter) an amount sufficient so that as of the Change in Control the trust has assets that are equal to or greater than the actuarial present value of all vested benefits to be provided under the Plan.  The amount to be contributed to the trust shall be determined by a disinterested actuary whose services are engaged by or on behalf of the Company, and who is to use reasonable actuarial assumptions regarding mortality and discount or interest rates in making all determinations regarding funding obligations hereunder.
 
(e)   Nonassignability .  Neither a Participant nor any other person shall have any right to sell, assign, transfer, pledge, anticipate, mortgage or otherwise encumber, hypothecate or convey in advance of actual receipt the amounts, if any, payable hereunder, or any part thereof, which are, and all rights to which are, expressly declared to be nonassignable and nontransferable.  No part of any amount payable shall, prior to actual payment, be subject to seizure or sequestration for the payment of any debts, judgments, alimony or separate maintenance owed by a Participant or any other person, nor shall such amounts or rights to such amounts be transferable by operation of law in the event of a Participant’s or any other person’s bankruptcy or insolvency.
 
(f)   Not a Contract of Employment .  The terms and conditions of this Plan shall not be deemed to constitute a contract of employment or service between the Company and any Participant, and Participants (and Participants’ Beneficiaries and spouses) shall have no rights against the Company except as may otherwise be specifically provided herein.  Moreover, nothing in this Plan shall be deemed to give a Participant the right to be retained in the employment or service of the Company, or to interfere with the right of the Company to discipline or discharge any Participant at any time.
 
(g)   Validity .  If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts hereof, but this Plan shall be construed and enforced as if such illegal and invalid provision had never been inserted herein.
 
(h)   Successors .  The provisions of this Plan shall bind and inure to the benefit of the Company and its successors and assigns, and the Company shall require all of its successors and assigns to expressly assume its obligations hereunder.  The term “successors,” as used herein, shall include any corporate or other business entity which shall, whether by merger,
 

 
-7-

 

(i)   consolidation, purchase or otherwise, acquire all or substantially all of the business or assets of the Company.
 
(j)   Tax Withholding .  The Company shall have the right to require Participants to remit to the Company an amount sufficient to satisfy federal, state and/or local tax withholding requirements, or to deduct from payments made pursuant to the Plan amounts sufficient to satisfy any such tax withholding requirements.
 
(k)   FICA Taxation .  If any benefit under the Plan is taxable to a Participant under the Federal Insurance Contributions Act (FICA) (as a result of section 3101 or 3121 of the Code or successor provisions), a payment may be made to the Participant from the Plan, and the Participant’s benefit under the Plan shall be reduced accordingly, to pay the applicable FICA tax withholding amount, and the federal, state and local income and FICA tax withholding applicable to the accelerated payment, in accordance with section 409A of the Code.
 
(l)   Governing Law .  The provisions of this Plan shall be construed and interpreted according to the laws of the State of New Jersey, except as preempted by Federal law.
 
IN WITNESS WHEREOF, the Company has caused the Plan to be adopted as of the Effective Date.
 
UNIVERSAL DISPLAY CORPORATION
   
   
   
By:
/s/ Sidney D. Rosenblatt                                            
   
Name:
Sidney Rosenblatt                                 
   
Title:
CFO                                                 

 
-8-

 

Exhibit A
 
Schedule of Retirement Benefits
 
Participants in the Plan and each Participant’s Classification under the Plan
 

Name of Participant
Classification
Date of Hire
Steven V. Abramson
50% class
May 13, 1996
Sidney D. Rosenblatt
50% class
June 1, 1995
Julia J. Brown
50% class
June 22, 1998
Janice K. Mahon
50% class
January 2, 1997
Michael Hack
50% class
October 11, 1999

1.  
Full SERP Benefit.
 
Each Participant shall be entitled to receive a full SERP benefit if the Participant’s employment with the Company terminates, other than for Cause, on or after the Participant attains age 65 with at least 20 Years of Service.  The full SERP benefit will be actuarially equivalent to the Normal Retirement Benefit described in paragraph 2 below.
 
2.  
Normal Retirement Benefit.
 
(a)   The “Normal Retirement Benefit” for a Participant will be calculated at the commencement date of the SERP benefit as an annual benefit, payable in the form of a single life annuity for the lifetime of the Participant, equal to the following percentage of the Participant’s Annual Base Salary:
 
(i)   For a Participant in the 50% class, 50% of Annual Base Salary.
 
(ii)   For a Participant in the 25% class, 25% of Annual Base Salary.
 
(iii)   For a Participant in the 15% class, 15% of Annual Base Salary.
 
(b)   The SERP benefit will be the actuarial equivalent of the Normal Retirement Benefit, will be subject to reduction, if applicable, as described below, and will be payable as described in paragraph 5 below.  The Participant’s life expectancy for purposes of calculating the SERP benefit will be determined as of the commencement date of the SERP benefit, except as otherwise provided in paragraph 7 below.
 
3.  
Prorated SERP Benefit and Vesting
 
(a)   Prorated SERP Benefit for Certain Terminations After Age 65 .  If a Participant’s employment terminates for any reason other than Cause on or after age 65, and the Participant has completed at least 15 Years of Service but less than 20 Years of Service, the Participant shall
 

 
-9-

 

(b)   be entitled to receive a prorated SERP benefit equal to the Normal Retirement Benefit multiplied by a fraction, the numerator of which is the number of Years of Service as measured from the Participant’s date of hire through the date of the Participant’s termination of employment (but not in excess of 20), and the denominator of which is 20.
 
(c)   Prorated SERP Benefit upon Involuntary Termination of Employment .  If the Company terminates a Participant’s employment without Cause before the Participant attains age 65, and the Participant has completed at least 15 Years of Service, the Participant shall be entitled to receive a prorated SERP benefit equal to the Normal Retirement Benefit multiplied by a fraction, the numerator of which is the number of Years of Service as measured from the Participant’s date of hire through the date of the Participant’s termination of employment (but not in excess of 20), and the denominator of which is 20.  No SERP benefit shall be paid if the Participant has less than 15 Years of Service, except in the case of Change in Control, as described below.
 
(d)   Vesting .  Each Participant shall vest in his or her SERP benefit when the Participant (i) attains age 65 with at least 15 Years of Service (in which case the vested SERP benefit will be a prorated benefit as described in subparagraph (a) above) or (ii) attains age 65 with at least 20 Years of Service.
 
4.  
Disability.
 
(a)   A Participant’s separation from service with the Company on account of Disability will be treated as a termination by the Company without Cause, and the Participant’s SERP benefit will be calculated accordingly.
 
(b)   The determination as to whether a Participant has a separation from service on account of Disability shall be made by the Committee in its sole discretion.  In making this determination, the Committee shall consider whether the Participant has been determined to be eligible for long-term disability benefits under any disability benefit plan sponsored by the Company, or for federal Social Security disability benefits.  The Committee may, in its discretion and based on such facts and circumstances as the Committee deems appropriate, determine that a Participant has a separation from service on account of Disability if the Participant has incurred a long-term physical or mental incapacity but is not eligible for long-term disability benefits under a disability benefit plan sponsored by the Company or for federal Social Security disability benefits.
 
5.  
Payment of SERP Benefit.
 
Except as otherwise provided in paragraph 7 below and subject to the six-month delay under section 409A of the Code, if applicable, if a Participant is entitled to receive a SERP benefit, the SERP benefit will be paid in equal monthly installments over 10 years, beginning within 30 days after the later of (i) the date of the Participant’s termination of employment with the Company, or (ii) the date on which the Participant attains age 65.
 

 
-10-

 

Death Benefits.
 
(a)   If a Participant dies after the Participant begins receiving a SERP benefit (or if a Participant is entitled to begin receiving a SERP benefit and dies after the commencement date set forth in paragraph 5 but before payments commence), the Participant’s Beneficiary shall receive any unpaid installments of the SERP benefit that would have been payable to the Participant had the Participant not died.  The SERP benefit shall continue to be paid on the same schedule as in effect at the date of the Participant’s death.
 
(b)   If a Participant dies while employed by the Company after attaining age 65 and with at least 15 Years of Service, the Participant’s Beneficiary will receive a SERP benefit equal to the benefit that the Participant would have been entitled to receive if the Participant’s employment had terminated immediately before his or her death, based on the life expectancy of the Participant as if he or she were living on the commencement date of the benefit.  The death benefit will be paid in equal monthly installments over 10 years, beginning within 30 days after the date of the Participant’s death.
 
(c)   In all other circumstances, if a Participant dies, no benefit will be paid under the Plan with respect to the Participant, except in the event of a Change in Control.  For the avoidance of doubt, if a Participant who terminates employment as described in paragraph 3(b) dies before the commencement date in paragraph 5, no benefit will be paid under the SERP, except in the event of a Change in Control.
 
6.  
Change in Control.
 
(a)   In the event of a Change in Control, each Participant who is then an employee of the Company shall be immediately vested in his or her SERP benefit as described in subparagraph (b) below, effective as of the date of the Change in Control, and there shall be no forfeiture of the SERP benefit resulting from the Participant’s death or any termination of the Participant’s employment thereafter.  In the event of a Change in Control, any Participant who is no longer an employee of the Company and who is then living and entitled to a SERP benefit under paragraph 3(b) shall be immediately vested in such SERP benefit, and the SERP benefit will not be forfeited if the Participant dies before the commencement date in paragraph 5.  Except as provided in subparagraph (c) or (d) below, each Participant’s SERP benefit shall be paid in accordance with paragraph 5 above.
 
(b)   In the event of a Change in Control, the vested SERP benefit of each Participant will be calculated by multiplying the Participant’s Normal Retirement Benefit as otherwise applicable (without regard to the Change in Control) by a fraction, the numerator of which is the number of Years of Service measured from the Participant’s date of hire through the date of the Change in Control (but not in excess of 20), and the denominator of which is 20; provided, however, that no adjustment shall reduce the Participant’s SERP benefit if the SERP benefit is already vested (without regard to the Change in Control) as of the date of the Change in Control.  For active Participants, the SERP benefit will be calculated as of the date of the Change in Control, based on Years of Service and Base Salary as of the date of the Change in Control and as if the commencement date were the later of the date of the Change in Control or the date on which the Participant attains age 65.  For Participants who are no longer employees of the
 

 
-11-

 

(c)   Company and whose benefit is not in pay status, the SERP benefit will be calculated according to the assumptions that would have been used had the Participant lived until the commencement date set forth in paragraph 5 and then begun receiving a SERP benefit.  There shall be no increase or decrease in SERP benefits, including on account of continued Years of Service of changes in Base Salary, after a Change in Control.
 
(d)   If an event occurs that constitutes a Change in Control as defined in the Plan, and such Change in Control event also qualifies as “a change in the ownership or effective control of the corporation, or in the ownership of a substantial portion of the assets of the corporation,” as that phrase is defined for purposes of Section 409A of the Code (a “ 409A Change in Control ”), then each Participant (including any Participant whose benefit is in pay status or Participant who is entitled to receive a benefit under the Plan in the future) shall receive a lump sum cash payment equal to the actuarially equivalent present value of the Participant’s vested SERP benefit under the Plan.  The present value of a SERP benefit that is in pay status shall be the lump sum present value of the remaining SERP payments.  The actuarial assumptions will be reasonably specified by the Committee before the Change in Control as described in paragraph 9(b) below.  The lump sum payment shall be made upon or within 30 days following the date of the 409A Change in Control.  After payment of the lump sum, the Participant shall thereafter have no entitlement to any further benefit under the Plan.
 
(e)   If a 409A Change in Control occurs after a Participant’s termination of employment without Cause, the Participant has a Change in Control Agreement with the Company that provides for enhanced severance benefits in the event of an involuntary termination of employment by the Company or a constructive termination during the one year period preceding a Change in Control or, if sooner, the date the Company publicly announces an intention to consummate a Change in Control, the Participant becomes entitled to enhanced severance benefits under the Change in Control Agreement under such circumstances, and the Participant is not otherwise entitled to a SERP benefit under the Plan, the Participant will earn a SERP benefit upon the 409A Change in Control as follows:
 
(i)   The SERP benefit shall be calculated as described in paragraph 7(b), as if the commencement date were the later of the date of the 409A Change in Control or the date on which the Participant attains age 65.
 
(ii)   The  SERP benefit will be paid in a lump sum payment upon or within 30 days following the date of the 409A Change in Control.
 
7.  
Forfeiture.
 
No Participant shall be entitled to a benefit under the Plan unless the Participant remains employed with the Company until the Participant meets the applicable requirements set forth above for a SERP benefit.  Any Participant whose employment terminates for any reason before meeting the applicable requirements set forth above shall forfeit any benefit otherwise payable to the Participant under the Plan.
 

 
-12-

 

8.  
Calculation Methodology.
 
(a)   Annual Base Salary .  For purposes hereof, “Annual Base Salary” shall mean 12 times the average monthly base salary (including any car allowance and including any deferrals or other salary reduction authorized amounts under any of the Company’s benefit plans or programs) paid or payable to the Participant by the Company during the 24-month period immediately preceding the Participant’s date of termination of employment with the Company, or, if required under subparagraph 7(b) above, the date of a Change in Control.
 
(b)   Calculation of Benefit at Commencement Date .  If a Participant is entitled to receive a SERP benefit under the Plan, the Company will calculate the lump sum present value of the Normal Retirement Benefit (reduced, if applicable, based on Years of Service as described above) as of the commencement date of the SERP benefit, based on the life expectancy of the Participant as of the commencement date of the SERP benefit under paragraph 5 above (or, if applicable, as provided in paragraph 7).  The present value of the benefit will be paid in equal monthly installments over 10 years as described in paragraph 5 above (or, if applicable, as provided in paragraph 7).  The 10-year period will be measured from the applicable commencement date.  The Committee shall use such reasonable actuarial assumptions as it deems appropriate to calculate the present value of the benefit, provided that, unless the Committee determines otherwise before a Change in Control, the following assumptions shall be used:
 
Mortality:                      RP 2000 mortality table
 
Interest:                      6%
 
9.  
Section 409A.
 
Notwithstanding the foregoing, all payments made under this Schedule of Retirement Benefits shall be made in accordance with the requirements of section 409A of the Code, including the six-month delay described in Section 3(d) of the Plan, if applicable.
 

 
-13-

 

Exhibit B
 
Rules for Special Participants
 
Notwithstanding Exhibit A, the following special provisions apply to Steven V. Abramson and Sidney D. Rosenblatt (“Special Participants”):
 
1.  
Full SERP Benefit.
 
Each Special Participant shall each be entitled to receive a full SERP benefit if his employment with the Company terminates, other than for Cause, (i) on or after the Special Participant completes at least 20 Years of Service, or (ii) on or after the Special Participant attains age 65 with at least 15 Years of Service.  The full SERP benefit will be actuarially equivalent to the Normal Retirement Benefit described in paragraph 2 below.
 
2.  
Normal Retirement Benefit.
 
(a)   The “Normal Retirement Benefit” for a Special Participant will be calculated at the commencement date of the SERP benefit as an annual benefit equal to 50% of the Special Participant’s Annual Base Salary, payable in the form of a joint and 100% survivor annuity for the lifetimes of the Special Participant and his surviving spouse, if any.  For purposes of the Plan, the surviving spouse will be the Special Participant’s spouse as of the date of the Special Participant’s termination of employment with the Company or, if sooner, the date of a Change in Control.
 
(b)   The SERP benefit will be the actuarial equivalent of the Normal Retirement Benefit and will be subject to reduction, if applicable, as described below.  The life expectancies of the Special Participant and his surviving spouse for purposes of calculating the SERP benefit will be determined as of the commencement date of the SERP benefit, except as otherwise provided in subparagraph 4(b) below or paragraph 7 of Exhibit A.  If the Special Participant’s spouse is not living at the commencement date of the SERP benefit, the SERP benefit will be based only on the life expectancy of the Special Participant at the commencement date of the SERP benefit.
 
3.  
Prorated Benefit and Vesting.
 
(a)   Prorated SERP Benefit upon Involuntary Termination of Employment .  If the Company terminates a Special Participant’s employment without Cause and the Special Participant has completed at least 10 Years of Service but less than 20 Years of Service (and before the Special Participant has attained age 65 with at least 15 Years of Service), the Special Participant shall be entitled to receive a prorated SERP benefit equal to the Normal Retirement Benefit multiplied by a fraction, the numerator of which is the number of Years of Service as measured from the Special Participant’s date of hire through the date of the Special Participant’s termination of employment (but not in excess of 20), and the denominator of which is 20.  No SERP benefit shall be paid if the Special Participant has less than 10 Years of Service, except in the case of Change in Control, as described below.
 

 
-14-

 

(b)   Vesting .  Each Special Participant shall vest in his SERP benefit when the Special Participant (i) completes 20 Years of Service, or (ii) attains age 65 with at least 15 Years of Service.
 
4.  
Death Benefits.
 
(a)   If a Special Participant dies after the Special Participant begins receiving a SERP benefit (or if a Special Participant is entitled to begin receiving a SERP benefit and dies after the commencement date in paragraph 5 of Exhibit A but before payments commence), the Special Participant’s Beneficiary shall receive any unpaid installments of the SERP benefit that would have been payable to the Special Participant had the Special Participant not died.  The SERP benefit shall continue to be paid on the same schedule as in effect at the date of the Special Participant’s death.
 
(b)   If a Special Participant dies while employed by the Company after attaining age 65 and with at least 10 Years of Service, and the Special Participant has a surviving spouse, the surviving spouse will receive a SERP benefit equal to the 100% survivor annuity portion of the benefit that the Special Participant would have been entitled to receive if the Special Participant’s employment had terminated immediately before his death.  The benefit shall be calculated as the applicable SERP benefit described above for the Special Participant, but based only on the life expectancy of the surviving spouse as of the commencement date of the benefit.  The death benefit will be paid in equal monthly installments over 10 years, beginning within 30 days after the date of the Participant’s death.
 
(c)   If a Special Participant dies while employed by the Company before attaining age 65 but after completing at least 10 Years of Service, and the Special Participant has a surviving spouse, the surviving spouse will receive a SERP benefit when the Special Participant would have attained age 65.  The SERP benefit to the surviving spouse will be equal to the 100% survivor annuity portion of the benefit that the Special Participant would have been entitled to receive if the Special Participant’s employment had terminated immediately before his death, provided the surviving spouse is still living at the date on which the Special Participant would have attained age 65.  The benefit shall be calculated as the applicable SERP benefit described above for the Special Participant, but based only on the life expectancy of the surviving spouse as of the commencement date of the benefit.  The death benefit will be paid in equal monthly installments over 10 years, beginning within 30 days after the date on which the Special Participant would have attained age 65, and will be paid only if the surviving spouse is living on such commencement date.  If the surviving spouse dies after beginning to receive a SERP benefit, the personal representative of the spouse’s estate shall receive any unpaid installments of the SERP benefit that would have been paid had the spouse not died.
 
(d)   In all other circumstances, if a Special Participant dies, no benefit will be paid under the Plan with respect to the Special Participant, except in the event of a Change in Control.  For the avoidance of doubt, if a Special Participant who terminates employment as described in paragraph 3(a) of this Exhibit B dies before the commencement date in paragraph 5 of Exhibit A, no benefit will be paid under the SERP, except in the event of a Change in Control.
 

 
-15-

 

(e)   Change in Control.
 
The Change in Control provisions of Exhibit A shall apply, except that the reference in paragraph 7(a) of Exhibit A to “paragraph 3(b)” shall include paragraph 3(a) of this Exhibit B.
 
5.  
Incorporation of Exhibit A.
 
In all other respects, Exhibit A shall apply to each Special Participant.
 

 

 
-16-

 

 

UNIVERSAL DISPLAY CORPORATION
EQUITY COMPENSATION PLAN

EQUITY RETENTION AGREEMENT


This EQUITY RETENTION AGREEMENT (this “ Agreement ”), effective as of March 18, 2010 (the “ Date of Grant ”), is delivered by Universal Display Corporation (the “ Company ”), to Steven V. Abramson (the “ Grantee ”).
 
RECITALS
 
The Universal Display Corporation Equity Compensation Plan (the “ Plan ”) provides for the grant of Stock Awards in accordance with the terms and conditions of the Plan.
 
The Compensation Committee of the Board of Directors of the Company (the “ Committee ”) has determined that it is in the best interests of the shareholders to make a significant Stock Award to the Grantee, subject to the restrictions set forth in this Agreement, as an inducement for the Grantee to:
 
·  
Devote substantial time and attention to promotion and development of the Company at a time that is important for the future success of the Company;
 
·  
Maintain a significant long-term ownership interest in the Company;
 
·  
Continue in employment in order to ensure continuity of leadership and vision for the Company; and thereby
 
·  
Increase shareholder value.
 
The Committee has determined that the Stock Award is reasonable and appropriate compensation for the services to be provided by the Grantee to the Company.  References in this Agreement to capitalized terms not defined herein shall have the meanings given to those terms in the Plan.
 
NOW, THEREFORE, the parties to this Agreement, intending to be legally bound, hereby agree as follows:
 
1.   Stock Award .  As approved by the Committee, the Company hereby grants to the Grantee 250,000 shares of common stock of the Company, subject to the terms, conditions and restrictions set forth below and in the Plan (the “ Stock Award ”).
 
2.   Vesting and Restriction on Disposition of the Stock Award .
 
(a)   The Stock Award shall become vested according to the following schedule, if the Grantee continues to be employed by the Company from the Date of Grant until the applicable vesting date.
 
 
Page 1 of 4

 
 
Vesting Date
 
Vested Shares
First Anniversary of Date of Grant
 
50,000
Second Anniversary of Date of Grant
 
50,000
Third Anniversary of Date of Grant
 
50,000
Fourth Anniversary of Date of Grant
 
50,000
Fifth Anniversary of Date of Grant
 
50,000

The vesting of the Stock Award shall be cumulative, but shall not exceed 100% of the Stock Award.
 
(b)   Notwithstanding the foregoing, the Stock Award shall vest in accordance with the terms of the Grantee’s Amended and Restated Change in Control Agreement dated November 4, 2008, between the Company and the Grantee (the “ Change in Control Agreement ”) in the event of a Change in Control, as defined in the Change in Control Agreement (a “ Change in Control ”).
 
(c)   If the Grantee ceases to be employed by the Company for any reason before the Stock Award is fully vested, the shares of the Stock Award that are not then vested shall be forfeited and must be immediately returned to the Company.  The Stock Award (whether or not vested) may also be forfeited under the circumstances described in Section 4 below.
 
(d)   In no event may any unvested shares of the Stock Award be assigned, transferred, pledged or otherwise disposed of or encumbered by the Grantee before the shares vest.  After shares of the Stock Award vest, the vested shares (net of any applicable tax withholding) may not be assigned, transferred, pledged or otherwise disposed of or encumbered by the Grantee until the fifth anniversary of the of vesting of said shares, except in the event of the Grantee’s death or a Change in Control.  With respect to each share subject to the Stock Award, the “ Restriction Period ” is the period beginning on the Date of Grant and ending on the first to occur of the fifth anniversary of the date of vesting of such share, the Grantee’s death or a Change in Control.  Any attempt to assign, transfer, pledge or otherwise dispose of or encumber the shares contrary to the provisions hereof, and the levy of any execution, attachment or similar process upon such shares, shall be null, void and without effect.
 
3.   Issuance of Certificates .
 
(a)   Stock certificates representing the Stock Award, with appropriate legends reflecting the restrictions under this Agreement, may be issued by the Company to the Grantee or may be held in escrow by the Company during the Restriction Period, as determined by the Committee.  When the Grantee obtains a vested right to shares of the Stock Award, the Grantee shall have the right to receive a certificate representing the vested shares (net of any applicable tax withholding), with appropriate legends reflecting the restrictions under this Agreement.  During the Restriction Period, the Grantee shall receive any cash dividends with respect to the shares of the Stock Award, may vote the shares of the Stock Award and may participate in any distribution pursuant to a plan of dissolution or complete liquidation of the Company.  In the event of a dividend or distribution payable in stock or other property or a reclassification, split up or similar event during the Restriction Period, the shares or other property issued or declared
 

 
Page 2 of 4

 
(b)   with respect to the Stock Award shall be subject to the same terms and conditions relating to vesting and transfer as the shares to which they relate.
 
(c)   The Company’s obligation to deliver shares pursuant to the Stock Award shall be subject to all applicable laws, rules and regulations and also to such approvals by governmental agencies as may be deemed appropriate to comply with relevant securities laws and regulations.
 
4.   Clawback .  Notwithstanding any provisions of this Agreement to the contrary, with respect to each share subject to the Stock Award  (whether or not vested), the share shall be forfeited, and must be immediately returned to the Company, upon request by the Committee in the event that, during the Restriction Period for such share, (i) the Grantee materially breaches a written non-competition, non-solicitation or confidentiality agreement between the Grantee and the Company and the Grantee fails to cure the breach (if such breach is curable) within 30 days after receiving written notice from the Company of the breach; (ii) the Grantee commits an act of dishonesty, fraud, embezzlement or theft in connection with his duties or in the course of the Grantee’s employment with the Company; (iii) the Grantee is convicted of a felony or a crime of moral turpitude; or (iv) the Grantee engages in actions that are materially detrimental to the Company, including, without limitation, any actions that result in a material restatement of the financial statements of the Company.
 
5.   Grant Subject to Plan Provisions .  This grant is made pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan.  The grant is subject to interpretations, regulations and determinations concerning the Plan established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) the registration, qualification or listing of the shares, (ii) changes in capitalization of the Company, and (iii) other requirements of applicable law.  The Committee shall have the authority to interpret and construe the grant pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.
 
6.   Tax Withholding .  Withholding for any federal, state, local or other taxes required with respect to the vesting of the Stock Award shall be governed by the Plan, except that the Grantee may elect to satisfy any tax withholding obligation of the Company with respect to the Stock Award by having shares withheld up to an amount that does not exceed the minimum applicable withholding tax rate for federal (including FICA), state, local and other tax liabilities.  The Company shall establish procedures for such an election by the Grantee.
 
7.   No Employment or Other Rights .  This grant shall not confer upon the Grantee any right to be retained by or in the employ of the Company and shall not interfere in any way with the right of the Company to terminate the Grantee’s employment at any time. The right of the Company to terminate at will the Grantee’s employment at any time for any reason is specifically reserved.
 
8.   Assignment by Company .  The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates.  This Agreement may be assigned by the Company without the Grantee’s consent.
 
 
Page 3 of 4

 
9.   Applicable Law .  The validity, construction, interpretation and effect of this instrument shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to the conflicts of laws provisions thereof.
 
10.   Notice .  Any notice to the Company provided for in this instrument shall be addressed to the Company care of the General Counsel at 375 Phillips Boulevard, Ewing, New Jersey 08618, and any notice to the Grantee shall be addressed to such Grantee at the current address shown on the payroll of the Company, or to such other address as the Grantee may designate to the Company in writing.  Any notice shall be delivered by hand or by a recognized courier service such as FedEx or UPS, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service.
 
IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this instrument, and the Grantee has placed his signature hereon.
 
UNIVERSAL DISPLAY CORPORATION
   
   
By:
/s/ Sidney D. Rosenblatt
   
Name:
Sidney Rosenblatt
   
Title:
CFO
   
Date:
4/1/10



I hereby accept the grant of the Stock Award described in this Agreement, and I agree to be bound by the terms of the Plan and this Agreement.  I hereby further agree that all of the decisions and determinations of the Committee with respect to the Stock Award and this Agreement shall be final and binding.


/s/ Steven V. Abramson
Grantee
 
4/1/10
Date


 
Page 4 of 4

 

 

UNIVERSAL DISPLAY CORPORATION
EQUITY COMPENSATION PLAN

EQUITY RETENTION AGREEMENT


This EQUITY RETENTION AGREEMENT (this “ Agreement ”), effective as of March 18, 2010 (the “ Date of Grant ”), is delivered by Universal Display Corporation (the “ Company ”), to Sidney D. Rosenblatt (the “ Grantee ”).
 
RECITALS
 
The Universal Display Corporation Equity Compensation Plan (the “ Plan ”) provides for the grant of Stock Awards in accordance with the terms and conditions of the Plan.
 
The Compensation Committee of the Board of Directors of the Company (the “ Committee ”) has determined that it is in the best interests of the shareholders to make a significant Stock Award to the Grantee, subject to the restrictions set forth in this Agreement, as an inducement for the Grantee to:
 
·  
Devote substantial time and attention to promotion and development of the Company at a time that is important for the future success of the Company;
 
·  
Maintain a significant long-term ownership interest in the Company;
 
·  
Continue in employment in order to ensure continuity of leadership and vision for the Company; and thereby
 
·  
Increase shareholder value.
 
The Committee has determined that the Stock Award is reasonable and appropriate compensation for the services to be provided by the Grantee to the Company.  References in this Agreement to capitalized terms not defined herein shall have the meanings given to those terms in the Plan.
 
NOW, THEREFORE, the parties to this Agreement, intending to be legally bound, hereby agree as follows:
 
1.   Stock Award .  As approved by the Committee, the Company hereby grants to the Grantee 250,000 shares of common stock of the Company, subject to the terms, conditions and restrictions set forth below and in the Plan (the “ Stock Award ”).
 
2.   Vesting and Restriction on Disposition of the Stock Award .
 
(a)   The Stock Award shall become vested according to the following schedule, if the Grantee continues to be employed by the Company from the Date of Grant until the applicable vesting date.
 
 
Page 1 of 4

 
 
Vesting Date
 
Vested Shares
First Anniversary of Date of Grant
 
50,000
Second Anniversary of Date of Grant
 
50,000
Third Anniversary of Date of Grant
 
50,000
Fourth Anniversary of Date of Grant
 
50,000
Fifth Anniversary of Date of Grant
 
50,000

The vesting of the Stock Award shall be cumulative, but shall not exceed 100% of the Stock Award.
 
(b)   Notwithstanding the foregoing, the Stock Award shall vest in accordance with the terms of the Grantee’s Amended and Restated Change in Control Agreement dated November 4, 2008, between the Company and the Grantee (the “ Change in Control Agreement ”) in the event of a Change in Control, as defined in the Change in Control Agreement (a “ Change in Control ”).
 
(c)   If the Grantee ceases to be employed by the Company for any reason before the Stock Award is fully vested, the shares of the Stock Award that are not then vested shall be forfeited and must be immediately returned to the Company.  The Stock Award (whether or not vested) may also be forfeited under the circumstances described in Section 4 below.
 
(d)   In no event may any unvested shares of the Stock Award be assigned, transferred, pledged or otherwise disposed of or encumbered by the Grantee before the shares vest.  After shares of the Stock Award vest, the vested shares (net of any applicable tax withholding) may not be assigned, transferred, pledged or otherwise disposed of or encumbered by the Grantee until the fifth anniversary of the of vesting of said shares, except in the event of the Grantee’s death or a Change in Control.  With respect to each share subject to the Stock Award, the “ Restriction Period ” is the period beginning on the Date of Grant and ending on the first to occur of the fifth anniversary of the date of vesting of such share, the Grantee’s death or a Change in Control.  Any attempt to assign, transfer, pledge or otherwise dispose of or encumber the shares contrary to the provisions hereof, and the levy of any execution, attachment or similar process upon such shares, shall be null, void and without effect.
 
3.   Issuance of Certificates .
 
(a)   Stock certificates representing the Stock Award, with appropriate legends reflecting the restrictions under this Agreement, may be issued by the Company to the Grantee or may be held in escrow by the Company during the Restriction Period, as determined by the Committee.  When the Grantee obtains a vested right to shares of the Stock Award, the Grantee shall have the right to receive a certificate representing the vested shares (net of any applicable tax withholding), with appropriate legends reflecting the restrictions under this Agreement.  During the Restriction Period, the Grantee shall receive any cash dividends with respect to the shares of the Stock Award, may vote the shares of the Stock Award and may participate in any distribution pursuant to a plan of dissolution or complete liquidation of the Company.  In the event of a dividend or distribution payable in stock or other property or a reclassification, split up or similar event during the Restriction Period, the shares or other property issued or declared
 

 
Page 2 of 4

 

(b)   with respect to the Stock Award shall be subject to the same terms and conditions relating to vesting and transfer as the shares to which they relate.
 
(c)   The Company’s obligation to deliver shares pursuant to the Stock Award shall be subject to all applicable laws, rules and regulations and also to such approvals by governmental agencies as may be deemed appropriate to comply with relevant securities laws and regulations.
 
4.   Clawback .  Notwithstanding any provisions of this Agreement to the contrary, with respect to each share subject to the Stock Award  (whether or not vested), the share shall be forfeited, and must be immediately returned to the Company, upon request by the Committee in the event that, during the Restriction Period for such share, (i) the Grantee materially breaches a written non-competition, non-solicitation or confidentiality agreement between the Grantee and the Company and the Grantee fails to cure the breach (if such breach is curable) within 30 days after receiving written notice from the Company of the breach; (ii) the Grantee commits an act of dishonesty, fraud, embezzlement or theft in connection with his duties or in the course of the Grantee’s employment with the Company; (iii) the Grantee is convicted of a felony or a crime of moral turpitude; or (iv) the Grantee engages in actions that are materially detrimental to the Company, including, without limitation, any actions that result in a material restatement of the financial statements of the Company.
 
5.   Grant Subject to Plan Provisions .  This grant is made pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan.  The grant is subject to interpretations, regulations and determinations concerning the Plan established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (i) the registration, qualification or listing of the shares, (ii) changes in capitalization of the Company, and (iii) other requirements of applicable law.  The Committee shall have the authority to interpret and construe the grant pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.
 
6.   Tax Withholding .  Withholding for any federal, state, local or other taxes required with respect to the vesting of the Stock Award shall be governed by the Plan, except that the Grantee may elect to satisfy any tax withholding obligation of the Company with respect to the Stock Award by having shares withheld up to an amount that does not exceed the minimum applicable withholding tax rate for federal (including FICA), state, local and other tax liabilities.  The Company shall establish procedures for such an election by the Grantee.
 
7.   No Employment or Other Rights .  This grant shall not confer upon the Grantee any right to be retained by or in the employ of the Company and shall not interfere in any way with the right of the Company to terminate the Grantee’s employment at any time. The right of the Company to terminate at will the Grantee’s employment at any time for any reason is specifically reserved.
 
8.   Assignment by Company .  The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates.  This Agreement may be assigned by the Company without the Grantee’s consent.
 

 
Page 3 of 4

 

9.   Applicable Law .  The validity, construction, interpretation and effect of this instrument shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to the conflicts of laws provisions thereof.
 
10.   Notice .  Any notice to the Company provided for in this instrument shall be addressed to the Company care of the General Counsel at 375 Phillips Boulevard, Ewing, New Jersey 08618, and any notice to the Grantee shall be addressed to such Grantee at the current address shown on the payroll of the Company, or to such other address as the Grantee may designate to the Company in writing.  Any notice shall be delivered by hand or by a recognized courier service such as FedEx or UPS, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service.
 
IN WITNESS WHEREOF, the Company has caused its duly authorized officer to execute this instrument, and the Grantee has placed his signature hereon.
 
UNIVERSAL DISPLAY CORPORATION
   
   
By:
/s/ Steven V. Abramson  
   
Name:
Steven V. Abramson  
   
Title:
President          
   
Date:
4/1/10            



I hereby accept the grant of the Stock Award described in this Agreement, and I agree to be bound by the terms of the Plan and this Agreement.  I hereby further agree that all of the decisions and determinations of the Committee with respect to the Stock Award and this Agreement shall be final and binding.


/s/ Sidney Rosenblatt                                 
Grantee
 
4/1/10  
Date


 
Page 4 of 4

 


Exhibit 31.1

CERTIFICATIONS REQUIRED BY
RULE 13a-14(a)/15d-14(a)

I, Steven V. Abramson, certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Universal Display Corporation (the “registrant”) for the quarter ended March 31, 2010;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 10, 2010
By:    /s/ Steven V. Abramson
 
Steven V. Abramson
 
President and Chief Executive Officer



Exhibit 31.2

CERTIFICATIONS REQUIRED BY
RULE 13a-14(a)/15d-14(a)

I, Sidney D. Rosenblatt, certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Universal Display Corporation (the “registrant”) for the quarter ended March 31, 2010;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 10, 2010
By:    /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer


Exhibit 32.1

CERTIFICATIONS REQUIRED BY
RULE 13a-14(b)/15d-14(b) AND 18 U.S.C. SECTION 1350

In connection with the quarterly report of Universal Display Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven V. Abramson, President and Chief Executive Officer of the Company, hereby certify, based on my knowledge, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 10, 2010
By:    /s/ Steven V. Abramson
 
Steven V. Abramson
 
President and Chief Executive Officer


Exhibit 32.2

CERTIFICATIONS REQUIRED BY
RULE 13a-14(b)/15d-14(b) AND 18 U.S.C. SECTION 1350

In connection with the quarterly report of Universal Display Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sidney D. Rosenblatt, Executive Vice President and Chief Financial Officer of the Company, hereby certify, based on my knowledge, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 10, 2010
By:    /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer